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Development of Co-processed Plasticized Cellulose Acetate for Sustained
Release Matrix Tablets
Abstract
Cellulose Acetate (CA) is a polymer extensively used in pharmaceutical applications. Because of the
hydrophobic nature and good film properties of CA, it is a good polymer candidate for sustained release
matrix tablets. Sustained release matrix tablets of cellulose acetate can be prepared by direct
compression or wet granulation methods. However, previous studies showed that a large amount of CA
was required to achieve the desired sustained release profile for a sparingly soluble drug and it was
difficult to formulate a highly water soluble drug by using CA as the retarding agent. Some studies
concluded that CA is very sensitive to the solubility of the drug and it is not suitable for retarding the
release for highly water soluble drugs.
There are two aims in our study. One is to modify the physical characteristic of the CA by using a coprocessing technique and increase the capacity of cellulose acetate to control the drug release rate. The
other is to modulate the drug release rate from the hydrophobic sustained release tablets and apply these
formulation strategies to reduce the burst release and enhance the final release.
Three different process methods including heat treatment, wet granulation and spray drying were used to
prepare the co-processed excipients with CA, plasticizer and inert excipient. The physical, flow and
compaction properties of the co-processed excipients were evaluated. All the co-processed excipients
prepared in this study all showed good flow characteristic. The spray dried process produced high porous
particles with large surface area. These particles required the least energy for plastic deformation during
compression and formed the tablets with highest mechanical strength. The wet granulated excipients
showed moderate plastic deformation capacity and resulting tablets with acceptable tensile strength. The
heat treated excipients required more energy to deform under compression pressure than the other two
methods and the resulting tablets have poor mechanical properties. For all preparation methods, addition
of 10% plasticizer increases the plasticity of the final excipient and decreases the tablet tensile strength.
The tablets containing hydrophilic plasticizer showed better tensile strength than the hydrophobic
plasticizer. The tensile strength of the tablets increased at low plasticizer concentration and the reverse
effect was observed on higher plasticizer concentration. Both wet granulated and spray dried excipients
showed desired flowability and acceptable compactability which makes them good excipient candidates
for direct compression formulation.
The sustained release characteristic of the co-processed excipients were evaluated by a freely water
soluble drug propranolol hydrochloride. The spray dried co-processed excipients demonstrated slower
drug release profile than the excipients prepared by the other two processing methods. The surface
morphology and initial water penetration study found the spray dried co-processed excipient can form a
continuous film like structure on the tablet surface which can effectively prevent water penetration and
drug diffusion. The drug release rate from the matrix tablets containing the novel spray dried excipients
can be decreased by increasing the hydrophobicity of the plasticizer and plasticizer concentration. The
drug release rate from the matrix was affected by the compression force but not the pH of the dissolution
medium. Based on porosity results and drug release mechanism study, addition of plasticizer to the coprocessed excipients showed a decrease in the drug release rate due to three reasons: a) decrease in the
porosity of the tablet; b) decrease in the effective diffusion coefficient; c) assist in maintaining tablet
structure during dissolution.
Three different types of pore formers were tried to modulate drug release characteristics from the plastic
inert matrix. With the help of pore formers lactose and Starch1500®, both observed improved final
release as well as increased burst release. When a small amount of hydrophilic polymer pore former was

incorporated into the formulation, it showed a limited burst release initially and complete release at final
stage. The optical microscopy results revealed the initial gel formation on the tablet surface with
development of a swollen porous structure in the matrix network during dissolution. The drug release rate
from this swellable porous matrix system is independent with the type and the particle size of hydrophilic
polymer and the pH of dissolution medium. The drug release rate increased when the hydrophilic polymer
concentration was less than 5%. Further increase of the hydrophilic polymer concentration to 10% did not
further increase the drug release rate. The low viscosity grade hydrophilic polymer resulted in rapid burst
release and incomplete final release, while middle to high viscosity grades of hydrophilic polymer avoided
these problems. The drug release is controlled by both drug diffusion and polymer relaxation. The Fickian
diffusion is the dominant release mechanism at the initial stage and the polymer relaxation becomes
dominant thereafter.
The spray dried co-processed excipient and the swollen porous matrix system were used to develop the
sustained release matrix formulation for three different drugs with different solubility. The optimized
formulations for these three drugs either meet the USP specifications or have similar dissolution profile to
the commercial product. For a freely water soluble drug propranolol hydrochloride, a roller compaction
method was applied to reduce the initial burst release. The tablets prepared by the roller compacted
granules showed suppressed burst release and complete final release. For the sparingly water soluble
drug theophylline, incorporating 10% hydrophilic polymer can successfully reduce the burst release as
well as improve the final release. Two successful sustained release formulations of the poorly water
soluble drug glipizide were obtained by using the plasticized co-processed excipient. Both of them have
similar dissolution profile as the commercial product Gluctrol XL®. But the formulation prepared with
lactose as pore former showed a large variation in dissolution profile while another formulation prepared
with both lactose and hydrophilic polymer as pore formers exhibited less variation in dissolution profile
and a higher f2 value.
In conclusion, the spray dried co-processed plasticized cellulose acetate developed in this study exhibits
good physical and mechanical properties. It can be used alone or combined with hydrophilic polymers to
control the release rate of the drugs with different solubility.
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ABSTRACT
Cellulose Acetate (CA) is a polymer extensively used in pharmaceutical
applications. Because of the hydrophobic nature and good film properties of CA, it is a
good polymer candidate for sustained release matrix tablets. Sustained release matrix
tablets of cellulose acetate can be prepared by direct compression or wet granulation
methods. However, previous studies showed that a large amount of CA was required to
achieve the desired sustained release profile for a sparingly soluble drug and it was
difficult to formulate a highly water soluble drug by using CA as the retarding agent.
Some studies concluded that CA is very sensitive to the solubility of the drug and it is not
suitable for retarding the release for highly water soluble drugs.
There are two aims in our study. One is to modify the physical characteristic of
the CA by using a co-processing technique and increase the capacity of cellulose acetate
to control the drug release rate. The other is to modulate the drug release rate from the
hydrophobic sustained release tablets and apply these formulation strategies to reduce the
burst release and enhance the final release.
Three different process methods including heat treatment, wet granulation and
spray drying were used to prepare the co-processed excipients with CA, plasticizer and
inert excipient. The physical, flow and compaction properties of the co-processed
excipients were evaluated. All the co-processed excipients prepared in this study all
showed good flow characteristic. The spray dried process produced high porous particles
with large surface area. These particles required the least energy for plastic deformation
during compression and formed the tablets with highest mechanical strength. The wet
granulated excipients showed moderate plastic deformation capacity and resulting tablets
with acceptable tensile strength. The heat treated excipients required more energy to
deform under compression pressure than the other two methods and the resulting tablets
have poor mechanical properties. For all preparation methods, addition of 10% plasticizer
increases the plasticity of the final excipient and decreases the tablet tensile strength. The
tablets containing hydrophilic plasticizer showed better tensile strength than the
hydrophobic plasticizer. The tensile strength of the tablets increased at low plasticizer
concentration and the reverse effect was observed on higher plasticizer concentration.
Both wet granulated and spray dried excipients showed desired flowability and
acceptable compactability which makes them good excipient candidates for direct
compression formulation.
The sustained release characteristic of the co-processed excipients were evaluated
by a freely water soluble drug propranolol hydrochloride. The spray dried co-processed
excipients demonstrated slower drug release profile than the excipients prepared by the
other two processing methods. The surface morphology and initial water penetration
study found the spray dried co-processed excipient can form a continuous film like
structure on the tablet surface which can effectively prevent water penetration and drug
diffusion. The drug release rate from the matrix tablets containing the novel spray dried
excipients can be decreased by increasing the hydrophobicity of the plasticizer and
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plasticizer concentration. The drug release rate from the matrix was affected by the
compression force but not the pH of the dissolution medium. Based on porosity results
and drug release mechanism study, addition of plasticizer to the co-processed excipients
showed a decrease in the drug release rate due to three reasons: a) decrease in the
porosity of the tablet; b) decrease in the effective diffusion coefficient; c) assist in
maintaining tablet structure during dissolution.
Three different types of pore formers were tried to modulate drug release
characteristics from the plastic inert matrix. With the help of pore formers lactose and
Starch1500®, both observed improved final release as well as increased burst release.
When a small amount of hydrophilic polymer pore former was incorporated into the
formulation, it showed a limited burst release initially and complete release at final stage.
The optical microscopy results revealed the initial gel formation on the tablet surface
with development of a swollen porous structure in the matrix network during dissolution.
The drug release rate from this swellable porous matrix system is independent with the
type and the particle size of hydrophilic polymer and the pH of dissolution medium. The
drug release rate increased when the hydrophilic polymer concentration was less than
5%. Further increase of the hydrophilic polymer concentration to 10% did not further
increase the drug release rate. The low viscosity grade hydrophilic polymer resulted in
rapid burst release and incomplete final release, while middle to high viscosity grades of
hydrophilic polymer avoided these problems. The drug release is controlled by both drug
diffusion and polymer relaxation. The Fickian diffusion is the dominant release
mechanism at the initial stage and the polymer relaxation becomes dominant thereafter.
The spray dried co-processed excipient and the swollen porous matrix system
were used to develop the sustained release matrix formulation for three different drugs
with different solubility. The optimized formulations for these three drugs either meet the
USP specifications or have similar dissolution profile to the commercial product. For a
freely water soluble drug propranolol hydrochloride, a roller compaction method was
applied to reduce the initial burst release. The tablets prepared by the roller compacted
granules showed suppressed burst release and complete final release. For the sparingly
water soluble drug theophylline, incorporating 10% hydrophilic polymer can successfully
reduce the burst release as well as improve the final release. Two successful sustained
release formulations of the poorly water soluble drug glipizide were obtained by using
the plasticized co-processed excipient. Both of them have similar dissolution profile as
the commercial product Gluctrol XL®. But the formulation prepared with lactose as pore
former showed a large variation in dissolution profile while another formulation prepared
with both lactose and hydrophilic polymer as pore formers exhibited less variation in
dissolution profile and a higher f2 value.
In conclusion, the spray dried co-processed plasticized cellulose acetate
developed in this study exhibits good physical and mechanical properties. It can be used
alone or combined with hydrophilic polymers to control the release rate of the drugs with
different solubility.
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Chapter 1. Introduction
Oral drug delivery is the most preferred route for delivering drugs to the body.
The popularity is due to the distinct advantages such as convenient to use, high patient
compliance, easy manufacture and relatively low cost. Traditional oral drug delivery
systems including oral suspensions, oral solutions, immediate release tablets and capsules
often cannot maintain the constant drug concentration in the blood, therefore frequent
doses were required for the drugs with a short half-life. In addition side effects may also
occur for the drugs with a narrow therapeutic window. Oral sustained release systems
have been developed since 1950 for solving these problems. These systems are designed
to control the drug release rate from gastrointestinal tract to extend the duration of action
and minimize the fluctuation of drug concentration and achieve better therapeutic
performance. In addition to the clinical advantages, the sustained release system can also
help to extend the product life-cycle. That becomes an important strategy for
management of product life-cycle for pharmaceutical industry.
The first sustained release product was developed in 1950 using the trade name
Spansules® [1]. It was a capsule form which contained a large number of beads. The
sustained release profile was achieved by coating a hydrophobic wax on beads containing
a sugar core and drug layer. Over the last six decades, a great number of sustained release
products were commercialized and a number of new sophisticated technologies were
developed and introduced to this area. The major commercialized sustained release
systems can be summarized as: matrix system, reservoir system and osmotic system.
Drug release is generally controlled by one or a combination of the following
mechanisms: drug diffusion, system swelling, system erosion or osmotic pressure.
Among all the sustained release systems, the matrix system is the simplest and the
most widely used sustained release system. This is due to the cost effective manufacture
process and the accommodation for a wide range of drugs with different chemical and
physical properties. The majority of the commercialized matrix systems are in the form of
tablets. The preparation process and equipment for preparation of matrix tablets is
usually similar to the conventional tablets.
1.1 Oral Matrix Sustained Release Tablet
In a matrix tablet, the drug is uniformly blended with other excipients including
rate-controlling material(s) and other inactive ingredients. Drug release is controlled
either by drug diffusion and/or matrix erosion. Based on the properties of rate-controlling
material, the matrix system can be divided into two types: hydrophilic matrix and
hydrophobic matrix.
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1.1.1 Hydrophilic matrix tablet
In a hydrophilic matrix tablet, the rate-controlling material is the hydrophilic
polymer. Upon contact with the aqueous medium or gastrointestinal fluid, the water
penetrates into the free spaces between the chains of hydrophilic polymer. The rigid
polymer relaxes and become flexible. A glassy to rubbery phase transformation of the
hydrophilic polymer occurs. As a result, the tablet swells and a viscous gel layer is
formed on the surface of tablet. The tablet consists of two different states: the glassy core
and rubbery gel layer. The lengthened and torturous diffusion pathway of the viscous gel
layer can hinder the release of embedded drug. As more water enters the tablet, the
concentration of the hydrophilic polymer at the surface dilutes and the disentanglement
concentration can be reached. The concentration at which polymeric chains are
disentangled is related to the rheological properties of the gels and corresponds to the
tablet erosion. The tablet can be completely eroded when water continues to penetrate
towards the core of the tablet through the gel layer. During dissolution, three driving
forces are present in the polymer network: the penetrating concentration gradient,
polymer concentration gradient and osmotic force. Drug release from the hydrophilic
matrices is controlled by diffusion and/or polymer erosion.
There are three broad categories of polymers that commonly used in the
preparation of hydrophilic matrices.
a)
b)
c)

Cellulose derivatives: methylcellulose (MC); hydroxyethylcellulose
(HEC); hydroxypropylcellulose (HPC); hydroxypropylmethylcellulose
(HPMC); and sodium carboxymethylcellulose (NaCMC).
Natural polymers: sodium alginate; xanthan gum; carrageenan; locust bean
gum; chitosan; guar gum; pectin and modified starches.
Synthetic polymers: polyacrylic acid derivative (carbopol); polyethylene
oxide (PEO), polyvinyl pyrrolidone (PVP).

These polymers also can be divided into ionic and non-ionic. Non-ionic polymers
such as HPMC and PEO will not be ionized in the water and their hydration and erosion
are independent of pH. On the contrary, the ionic polymers such as chitosan and
Carbopol exhibit pH dependent hydrophilicity due to ionization of the polymer chain
under a certain pH.
Of all the polymers, HPMC is one of the most widely used polymers in
hydrophilic matrices. It is cellulose ether containing methoxyl and hydroxypropyl groups.
Different substitutions and viscosity grades of HPMC are commercially available. The
key features and advantages of HPMC included [2]:
a)
b)
c)
d)

Non-ionic polymer resulting in pH independent drug release performance.
Stable within a wide pH range and resistant to enzymatic degradation.
Less chance for chemical interaction or complexation with other
formulation components.
Accommodation of various drugs and a high level of drug loading.
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e)
f)

Good compaction characteristics in both direct compression and
granulation.
Easy to manufacture.

Another widely used hydrophilic polymer is carbopol. It is a synthetic high
molecular weight ionic polymer prepared by crosslinking acrylic acid with allyl sucrose
or allylpentaerythritol. Carbopol is also available with different viscosity and particle size
grades such as 934P, 974P, 971P and 71G [3]. They are not soluble, but swellable in
water. Owing to the present of carboxyl group in the polymer chain, the swellability of
carbopol polymers is pH dependent and the maximum swellability is 1,000 times their
original volume at pH6.0 [4]. Unlike the traditional linear polymer like HPMC and HPC
which form continuous gel layer by the single entangled polymer chains, the crosslinked
carbopol polymer will form a discrete microgel made of many polymer particles. The
drug can be entrapped into this microgel and slowly release by diffusion. Since carbopol
doesn’t dissolve in the water, the erosion doesn’t take place in this system. When the
system is fully hydrated, the osmotic pressure generated inside the gel network will break
the structure of hydrogel by shedding off the discrete pieces. With this unique feature,
relatively small amount of the carbopol is required to formulate the hydrophilic matrix
tablet.
The factors involved in controlling drug release from hydrophilic matrix tablets
were extensively investigated. Drug release from the hydrophilic matrix tablets was less
affected by the process variables such as compaction pressure, mixing time and
granulation methods [5, 6]. On the other hand, the formulation variables including drug
properties, polymer properties, filler choice and geometric dimension of the matrix were
crucial to the drug release from the matrix tablets.
The drug release behavioral from the hydrophilic matrix tablet is a function of
drug solubility which was analyzed by the model-independent and model-dependent
methods [7]. The study revealed the primary rate limiting factor is matrix erosion for the
drugs with poor solubility. When the solubility of the drug is between 0.5mg/ml to
5mg/ml, the drug release rate was controlled by both matrix erosion and medium
infiltration into the matrix. In the case of drug solubility more than 5 mg/ml, the rate
limiting factor was only the infiltration of medium to the matrix but not the drug
solubility. In general, the primary release mechanism of water soluble drug is diffusion
and the erosion is the major release mechanism for water insoluble drug. The drugs with
high water solubility always exhibit fast release and the rapid initial release so called
burst release due to the rapid surface drug diffusion. It is a challenge for formulating the
highly water soluble drugs with high dose using the hydrophilic matrix tablet.
In order to obtain a complete gel formation and prolonged drug release, certain
polymer concentration should be used in the matrix tablet. Utilizing HPMC as an
example, 20%-50% is the typical usage level. For some of the water soluble drugs, when
the polymer concentration reaches to a particular level, future increase of the polymer
level would not sequentially suppress the drug release [8, 9]. The polymers with high
viscosity grades typically have a fast hydration rate and are more resistant to dilution and
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erosion. This result a strong and thicken gel layer and slower drug dissolution. The high
viscosity polymers are generally recommended for highly water soluble drug since the
strong and tortuous gel layer provides more resistance to drug diffusion. The particle size
of the hydrophilic polymer also can affect the drug release from the matrix tablet. The
hydrophilic polymers with smaller particle size have a rapid hydration rate and quick gel
formation, therefore better controlled release properties [2, 10] Some polymer
manufactures such as Dow chemical provide specific fine particle grades for controlled
release applications. It was reported the hydrophobicity of the polymer also plays a role
on the drug release.
Incorporation of filler to matrix tablet can improve the flow properties of the
granules and mechanical strength of the tablets. It modifies not only the physical
properties, but the filler can also manipulate the drug release from the matrix. It is a
common strategy for formulation development of the hydrophilic matrix tablet. Water
soluble fillers like polyethylene glycol, lactose can increase drug release, because the
water penetration was enhanced and the tortuosity of the gel matrix was decreased after
the water soluble filler leached out from the system [5]. The insoluble fillers like
dicalcium phosphate and microcrystalline cellulose exhibit a relatively slower release
rate. The water swellable filler partially pregelatinized maize starch (Starch 1500) was
found to have synergistic interaction with the polymer and prevented the water absorption
into the matrix, thus slowing down the drug release [7, 11].
Geometric factors, including the shape and size of the tablet were reported to
affect the drug release from the matrix tablet. The surface area to volume ratio (S/V) was
found to be one of the key variables. The tablets with large S/V exhibit fast drug release
rate since more surface is available for drug diffusion. The similar release profile can be
obtained from the tablets with same S/V, regardless the tablet shape and dose [12, 13].
For hydrophilic matrix tablet, the geometry of the tablet keeps changing and the S/V is
not constant during dissolution. This results in the variation of the drug release rate at
different time points. Modification of the geometry of the tablets to maintain the constant
S/V during dissolution was approved to be effective to achieve the constant release rate.
This modification includes the Geomatrix® technology (multi-layer tablet), Smartrix®
technology (triple-layered tablet with specific shape in core layer), Dome Matrix®
technology (tablet structure arranged by different elementary modules), cup-in-core
device and Donald shape tablets. However, many of these designs are very complicated
and difficult to manufacture [14].
The combination of a hydrophilic polymer with another hydrophilic or
hydrophobic polymer to achieve better drug release performance was extensively
investigated. The decreased burst release was observed when a hydrophobic polymer was
incorporated into the hydrophilic matrix. This was explained by the increase in the
hydrophobicity of the tablet surface and the decrease of water penetration into matrix [15,
16]. However, when a higher ratio of hydrophobic polymer was present in the matrix, it
disrupted gel strength and faster drug dissolution occurred [17-19]. The interaction
between the nonionic polymer HPMC and anionic polymer NaCMC helps to overcome
the burst effect and lag time associated with the individual polymers. A linear release
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profile can be achieved by use of this combination [20, 21]. Combination of the nonionic
polymer with the anionic polymer was also utilized to obtain a pH independent profile for
basic drugs. The strong interaction of the basic drug and the anionic polymer leads to the
formation of an insoluble drug-polymer complex. This complex retarded the drug release
from the matrix and minimized the pH effect [22, 23]. The similar phenomenon was
appeared while using the combination of nonionic polymer with a cationic polymer and
an anionic polymer with a cationic polymer [24-26].
In general, development of the hydrophilic matrix tablets is the state of the art
technique. Many formulation factors involved in the development need to be taken into
consideration in order to obtain the desired drug release profile and ideal in-vivo
performance.
1.1.2 Hydrophobic matrix tablet
The primary rate limiting components in a hydrophobic matrix tablet are water
insoluble polymers, waxes or combination of both. The examples of hydrophobic waxes
material include glycerides, fatty acids and alcohols, hydrogenated vegetable oils [17, 27,
28]. The commonly used hydrophobic polymers consist of ethyl cellulose (EC), cellulose
acetate (CA), methacrylic acid copolymers (Eudragit®), starch acetates and poly vinyl
acetate (PVA) [29-34].
In hydrophobic matrix tablets, the drug is mixed with the hydrophobic
components and other excipients, and then be compressed into a tablet. Sustained release
profile was achieved by the drug diffusion through the water filled capillary channels or
pores existing in tablet network. The drug release behaviors directly related to the
porosity and pore structure from the matrix [35]. Such type of matrix is inert in the
presence of water and gastrointestinal fluid, and maintains its size and dimensions during
drug dissolution. The liquid penetration through the matrix network is the rate-controlling
step. The typical mechanism of drug release is diffusion. The drug release from the
hydrophobic matrix tablet is a proportional to the square root of time and can be
described by the Higuchi equation [36].
The formulation factors and process factors which affect the drug release from the
hydrophobic matrix tablets were also investigated by many scientists. The drug
properties, particle size of the polymers, formulation variables and process variables were
critical factors of drug release from the hydrophobic matrix tablets.
Neau et al [37] studied the drug solubility effect on drug release mechanism from
ethylcellulose matrix tablets. Increased drug release rate with an increase of drug
solubility was observed for formulations with different drug loadings. At low drug
loading, the contribution of polymer relaxation to the drug release diminishes with
decreasing drug solubility. Drug solubility effect on drug release was also found in
cellulose acetate matrix tablet [38]. The sustained release profile was only obtained for
the sparingly water soluble drug theophylline, but not for highly soluble drug dyphylline
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and proxyphylline when cellulose acetate was used as the retarding agent. Additional
barrier-coating was required for the highly soluble drug formulations to prevent the
massive release and matrix erosion.
The particle size of the polymer is a very important factor in controlling the drug
release from the hydrophobic matrix tablet. The coarse grade of hydrophobic polymers
failed to achieve the sustained drug release profile while the same viscosity grade of fine
particles can effectively control the drug release [39]. According to the percolation
theory, fewer drug clusters can be formed when more polymer particles surrounded the
drug. Since more polymer particles were presented in the fine particle grades, slower
drug release can be obtained [40].
Dabbagh et al [41] investigated the effect of polymer concentration, compression
pressure and hydrophilic polymers on drug release from hydrophobic ethylcellulose
matrix tablets. The results demonstrated the influence of polymer concentration on drug
release rate. Decreased drug release rate was observed as the polymer concentration
increased in the matrix, however the polymer concentration did not alter the drug release
mechanism. The drug release rate was also affected by the compression pressure. The
drug release rate was decreased as the compression pressure was increased to 39.4 MNm2
initially. But as the compression pressure reached to the range of 78.7-393.7 MNm-2, the
drug release was relatively unaffected owing to the elasticity of the ethylcellulose. Drug
release rate was increased by incorporation of hydrophilic polymer NaCMC or HPMC
K4M to the hydrophobic matrix. Rapid water uptake and discontinuous gel formation
were responsible for the fast drug release profile.
Sadeghi et al [42] found the tensile strength of the matrix tablets was a critical
factor for drug release. The results showed the matrices prepared by the water soluble
drug propranolol hydrochloride and Eudragit RL or RS could not maintain the physical
dimension for a longer period of time. Addition of Aerosil® 200 increased tensile
strength of matrices and the tablets could retain their structure which decreased the drug
release rate. Azarmi et al [29] reported a thermal treating method to modulate the drug
release from Eudragit® RS and Eudragit® RL matrices. When the matrix tablets were
heat treated above the glass transition temperature of the polymers, decreased porosity
was observed and slower drug release was achieved from the Eudragit matrices.
Compared to the hydrophilic matrix tablets, hydrophobic matrix tablets provided
several advantages [17, 19]: a) suitable for highly water soluble drugs; b) drug release is
not influenced by the pH and ionic strength of dissolution medium; c) good stability at
varies moisture levels during storage. The major disadvantage of the hydrophobic matrix
tablet is the incomplete release of water insoluble drug during the gastrointestinal
transition time due to the insufficient concentration gradient [43]. To modulate drug
release from this type of matrix, soluble ingredients such as lactose and PEG are required
to incorporate into the formulation. The presence of soluble ingredient in the formulation
helps to form numerous pores in the hydrophobic matrix network for water penetration
and drug diffusion [44].
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1.2 Mathematic Models for Matrix System
1.2.1 Higuchi equation
In 1961, Higuchi published a mathematical equation to describe drug release from
matrix systems [11]. Although it was developed to describe the drug release profile from
the ointment initially, it was later modified to include different geometries and matrix
characteristics for describing the drug release from matrix tablets [36]. The basic
equation of Higuchi model is Equation 1-1:
Qt =

S2 Dε
τ

1
2

1

2C0 -εCS CS t =kt2

(Eq. 1-1)

where Qt is the cumulative amount of drug released in time t; S is the surface area of the
tablet; D denotes the drug diffusion coefficient in the matrix phase; Cs is the drug
solubility in the matrix; C0 represents the drug concentration in the matrix; ε is the
porosity; τ denotes the tortuosity of the matrix; and k is the dissolution rate constant.
Based on this equation, drug release at any given time is proportional to the
square root of the time. The release rate constant k are affected not only by the diffusion
coefficient , surface area and drug solubility in the matrix, but also by the matrix
properties porosity and tortuosity.
This equation was derived under pseudo steady state assumptions. The
assumptions include:
a)
b)
c)
d)
e)
f)
g)

Particle size of the drug are small compared to the average diffusion
distance;
The diffusion coefficient is constant during the dissolution process;
Perfect sink conditions are maintained during the dissolution process;
The only driving force is the diffusion;
The drug concentration in the matrix is greater than the drug solubility in
the dissolution medium;
There is no interaction between drug and matrix, the swelling or
dissolution of the polymer carrier must be negligible; and
Only one dimensional diffusion is taken into consideration for the
equation, the edge effects must be negligible.

Because of the assumption of the steady state diffusion, the Higuchi equation only
can be used to predict drug release less than 70%. If the percentage of drug release is
greater than 70%, Higuchi equation cannot give an accurate prediction.
The Higuchi equation is a simple and applicable equation in many cases not only
for hydrophobic matrix tablet but also in hydrophilic matrix tablet. When it applied for
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hydrophilic matrix tablet, it is only an empirical equation with square root rate constant
and could not characterize the system.
1.2.2 Power law equation
The power law equation is a semi-empirical equation to describe the drug release
from polymeric systems. The general equation is [45, 46]:
Mt/ M∞=k*tn

(Eq. 1-2)

where Mt is cumulative amount of drug released at time t, M∞ is cumulative amount of
drug released at infinite time; k is release constant incorporating structural and geometric
characteristics of the system, and n is the release exponent indicating the mechanism of
drug release.
This equation is derived by Peppas and co-workers, so it is also called Peppas
equation. It is a generalization of two independent drug release mechanisms. There are
Fickian diffusion and Case II transport. In most systems containing swellable polymers,
the drug release is additive result of polymer relaxation and drug diffusion.
The release exponent ‘n’ in the power law takes multiple values based on
geometry of the system. Different values of n for slab, cylindrical and spherical
geometries and corresponding release mechanisms are listed in Table 1-1.
Take the slab as an example, if the n values < 0.5 , the main mechanism is Fickian
diffusion; if the n value =1, Case-II transport which is the polymer relaxation is the rate
limiting process; if n value between 0.5 and 1, the “anomalous transport” takes place
where is the combination of both drug diffusion and swelling of the polymer.
The power law equation is a very simple and useful tool to determine the drug
release mechanism from the matrix system. It has been successfully applied to many
matrix systems [47, 48]. Similar as the Higuchi equation, the power law equation is only
valid for the first 70% of the release profile. However, it is too simple to offer a robust
prediction for complicated release phenomena. These empirical models can only predict
the release profile after certain release experiments are conducted and have limited
capability to predict how the release profiles will change as the chemical or network
properties of the system are varied.
Scientists have also made some modifications to expand the use of the equation.
A modification of the power law equation was made by incorporating the concept of lag
time [49].
M (t-tlag)/ M∞=k*(t-tlag)n
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(Eq. 1-3)

Table 1-1.

Release exponent “n” for devices with different geometry
Slab
<0.5
0.5-1
>1

Cylinder
<0.45
0.45-0.89
>0.89

Sphere
<0.43
0.43-0.85
>0.85
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Release mechanism
Fickian diffusion
Anomalous transport
Case transport

Another modification was performed by decoupling diffusion and “Case-II
transport” with the following expression [50]:
Mt/ M∞=k1*tm + k2*t2m

(Eq. 1-4)

where k1, k2 and m are constants. First term in the right hand of the equation represents
the contribution of Fickian diffusion (F) to overall drug release and the second term
represents the contribution of tablet structure relaxation (R). R/F ratio can be calculated
using Equation 1-5.
R/F = k2*tm/k1

(Eq. 1-5)

The dominant drug release mechanism can be determined by the R/F ratio at any
given time during dissolution. The drug release profile can be modulated based on the
release mechanism.
1.2.3 Hopfenberg model
The Hopfenberg model is developed to describe drug release from the degradable
or erodible drug delivery system [51, 52]. The general equation is:
Mt
M∞

=1-(1-

k0 t n
C0 a

)

Eq. 1-6

where Mt and M∞ are the cumulative absolute amounts of drug released at time t and at
infinite respectively; k0 is zero order rate constant; C0 denotes the uniform initial drug
concentration within the system; and a is the radius of a cylinder or sphere or the halfthickness of a slab; n is a shape factor representing spherical (n = 3), cylindrical (n=2) or
slab geometry (n = 1).
The model was developed by the following assumptions:
a)
b)
c)
d)

There is no edge and end effect.
The rate-limiting step of drug release is the surface erosion.
Time dependent internal or external diffusion resistances do not influence
matrix erosion.
Overall kinetics is a zero-order process.

The Hopfenberg model can be applied to a surface eroding polymer matrix system
with a zero order surface drug detachment. The drug release rate is proportional to the
surface erosion of the device.
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1.3 Cellulose Acetate (CA)
1.3.1 Chemical structure
Cellulose acetate (CA) is the acetate ester of cellulose. It was produced by the
reaction of acetic acid and acetic anhydride with purified cellulose in the present of
sulfuric acid. A further partial hydrolysis was used to remove sulfate and a certain
number of acetate groups under the controlled conditions. All of the three hydroxyl
groups located on the repeated unit of cellulose structure can react and form acetate
esters. The amount of esterfication can be controlled by the reaction conditions. The
chemical structure of CA is illustrated in Figure 1-1. It contains a cellulose backbone
which is a repeat unit of anhydrous glucose and connected by β-1, 4 glycosidic linkages.
The three hydroxyl groups were partially substituted by the acetyl group. The degree of
the substitution was expressed as the average number of acetyl group in one repeat unit.
The length of the cellulose chain and the degree of acetyl substitution directly affect the
physicochemical properties of CA.
1.3.2 Physicochemical properties of CA
Cellulose acetate is a tasteless, odorless white powder or pellet. It is generally
regarded as a nontoxic and nonirritant material. It is hydrophobic in nature and only
soluble in certain organic solvents such as acetone, methylene chloride-alcohol blends,
methyl acetate, dimethyl formamide, and dioxane. The solubility of CA is greatly
affected by the molecular weight and degree of substitution.
There are various grades of CA available on the market with different molecular
weight and degree of substitution as listed in Table 1-2. CA polymers have a relatively
high glass transition temperature 170–190°C and high melting point 230–300°C. The
glass transition temperature and melting point were increased as increasing the molecular
weight and degree of substitution of CA. The viscosity of CA polymers listed in
Table 1-2 was measured in 10% w/v organic solutions. The viscosity of CA polymers is
directly related to the molecular weight and range from10 to230 mPa.s (10–230 cP).
Even though there are various grades of CA available, only two of them were approved
by FDA for pharmaceutical application. There are CA 320S and CA 398-10 NF.
CA polymers were supplied as fine powder or pellet form. For the powder form,
the typical bulk density is 0.32g/cm3 and typical tap density is 0.4g/ cm3. More than 90%
of the powder can pass through 80 mesh sieve. These properties make the CA powder
suitable for direct compression application. The pellet form has to be dissolved in a
solvent, then form a film after solvent is evaporated.
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Figure 1-1.

Chemical structure of cellulose acetate

Table 1-2.

Physical and chemical properties of different grade of cellulose acetate

Viscositya Acetyl Degree of Hydroxyl Melting
(cP)
(%) substitution (%)
range
CA-320S
2.4
32.0
1.8
8.7
230-250
CA-398-3
11.4
39.8
2.4
3.5
230-250
CA-398-6
22.8
39.8
2.4
3.5
230-250
CA-398-10NF
38.0
39.8
2.4
3.5
230-250
CA-398-30
114.0
39.7
2.4
3.5
230-250
CA-394-60S
228.0
39.5
2.4
4.0
240-260
CA-435-75S
N/A
43.5
2.9
0.9
280-300
a
ASTM D 871(Formula A) and D 1343
b
Number average molecular weight in polystyrene equivalents
CA grades
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Tg °C

MWnb

180
180
182
185
189
186
185

38,000
30,000
35,000
40,000
50,000
60,000
122,000

1.3.3 Pharmaceutical application of CA
1.3.3.1 Osmotic drug delivery system
The osmotic drug delivery system is a novel delivery system developed in the
1970s which utilizes osmotic pressure as an energy source to control the drug release. It
typically consists of the tablet core and a semi-permeable coating layer with a laser
drilled hole on the coating membrane. The drug release from the osmotic delivery system
was controlled by the water flux rate, drug solubility and osmotic pressure which
generated by the osmogent. There are several types of osmotic delivery device on the
market including: elementary osmotic pump, push–pull osmotic pump, sandwiched
osmotic pump, liquid oral osmotic system, controlled porosity osmotic pump and
asymmetric osmotic system. The semi-permeable membrane is an essential part in an
osmotic delivery system. This membrane should be insoluble and permeable to the water
to pertain sufficient water flux, but relatively impermeable to the contents inside the
device to prevent the diffusion of drug and osmogent through the film. It has to be stable
and rigid enough to retain its integrity during drug dissolution.
CA is the most widely used polymer to form the membrane in osmotic drug
delivery system due to its excellent mechanical and semi-permeable properties. The
properties of the membrane are directly related to the water flux rate and therefore affect
the drug release rate. CA membrane has a relatively high water permeability compared to
other polymer membranes. The water permeability can be easily be adjusted by the acetyl
content of the CA, incorporation of plasticizer and the thickness of the membrane.
As the acetyl content increases, the permeability of CA membrane decreases and
water flux rate also decreases. Yuan et al [53] studied an osmotic pump tablet of
theophylline by using CA 320S or CA 398-10 NF as a coating membrane. The tablets
coated with low acetyl content CA (CA-320S) showed higher water permeability and
faster release rate of theophylline.
Studies have shown the type and the level of plasticizers can alter the properties
of CA film. In general, incorporation of plasticizer to the CA film lowers the glass
transition temperature, increases flexibility of film and decreases the strength of the film.
The water permeability of the CA film depends on the type of the plasticizer used in the
system. Usually, soluble plasticizers increase the water permeability and insoluble
plasticizers decrease the water permeability. Guo [54] reported the effect of water soluble
plasticizer PEG 600 on water permeability and physical properties of CA film. The water
permeability of CA films decreased as increasing PEG-600 to a minimum level due to the
antiplasticization effect. At higher concentration PEG 600, especially when the PEG 600
is over 30% (w/w), the dramatic increase of water permeability was found owing to the
plasticizer channels were formed in the CA films. Liu et al [55] studied the effect of the
nature of the plasticizers on the film properties as well as the drug release rate. Addition
of hydrophilic plasticizer PEG 200 improved the drug release whereas addition of
hydrophobic plasticizer triacetin suppressed the drug release from a monolithic osmotic
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tablet. Films containing PEG as plasticizer developed numerous pores after 24 hours
dissolution whereas films containing triacetin as plasticizer still remained a dense film
structure.
The thickness of the coating membrane is another factor that affects the drug
release from the osmotic system. The water permeability as well as the drug release rate
is typically inversely proportional to the thickness of the coating membrane. A study [56]
on nifedipine monolithic osmotic tablet found the drug release rate decreases as the
thickness of membrane increased from 85-340μm. But for the asymmetric osmotic
system, the thickness of the coating membrane was found to have a slight effect on drug
release rate. This is due to the existence of large numbers of open pores in the membrane.
The structure of the membrane played a more important role than the thickness [57].
1.3.3.2 Sustained release matrix system
As a water insoluble hydrophobic polymer, CA is widely used in a sustained
release matrix system. Sustained release matrix tablets prepared by cellulose acetate have
been investigated by using direct compression or wet granulation methods [38, 58-60]. In
most of the cellulose acetate matrix tablet formulations, additional binder was added to
improve the tensile strength of the tablets. The results showed drug solubility is an
especially important influence on the release rate. The CA matrix is capable of
controlling the release rate for a sparingly water soluble drug theophylline when a high
concentration of CA were presented in the tablet. But the satisfactory sustained release
profiles were difficult to obtain when the drug solubility is higher. This is due to
insufficient surrounding of CA to highly soluble drug particles. Additional barriercoating to the soluble drug particles can effectively prevent the massive drug release and
matrix erosion.
Another study [61] showed the longer compression dwell time is helpful to
prolong the drug release from the CA matrix. In order to keep integration of the matrix
tablet during dissolution, enough bonding caused by the fusion between the polymer
particles are required. The polymer fusion takes place whiles a temperature higher than
glass transition temperature of the polymer occurs during tablet compression. For CA
polymers with high glass transition temperature, a long dwell time and high compression
pressure are necessary to induce the fusion between the adjacent CA particles. It was
concluded that the longer dwell time (>20s) of the compression process was required to
form bonding by fusion to obtain the sustained drug release profile. But this method is
not practical for high speed tablet press production. The production rate will be very
limited if a long compression dwell time is applied.
Yuan et al [58] studied the formulation effect on the drug release from the
cellulose acetate (CA) or cellulose acetate butyrate (CAB) matrix tablet prepared by
direct compression process. It was concluded drug solubility, polymer concentration, type
and degree of substitution of polymer, and other excipients presented in the matrix tablets
are the key formulation factors. It was found that the tablet prepared by the more

14

hydrophobic polymer CAB showed slower drug release rate than CA. This research also
found admixing the plasticizer triethyl citrate (TEC) with CA can help to retard drug
release from the matrix tablet.
CA is also used for preparation of matrix microspheres [62-64]. The low bulk
density and hydrophobic nature make CA suitable in preparation of a gastric floating
system. The smooth and spherical microspheres can be obtained by using CA as a carrier
material with encapsulation efficiency ranging from 73% to 98%. The microspheres
sustained the drug release and remained floating for over 10 hours. The drug release rate
from the microsphere decreased as the mean particle size and the concentration of the
polymer increased [63].
1.3.3.3 Other applications
As an odorless and tasteless polymer with excellent film properties, CA is also
used for the taste masking application [65, 66]. When CA based coating was applied on
the surface of acetaminophen granules, the unpleasant bitter taste of acetaminophen
diminished. A taste masked chewable tablet can be obtained by compressing these
granules with other excipients. Yu et al [66]coated the levofloxacin particles by using
the combination of CA and other pH sensitive polymer Eudragit® E-100. The improved
palatability of drug was obtained. These taste masked drug particles were suitable for oral
liquid dosage form.
CA film can be used as rate controlling membrane for transdermal delivery
system [47, 67]. The smooth and flexible film can be prepared by using CA and
plasticizer. The plasticized films are permeable for both water vapor and drug. The
permeability coefficient of the drug is dependent on the type of plasticizer and the
thickness of the film. High permeability coefficient was observed when water soluble
plasticizer was applied. Drug diffusion rate increased as thickness of the film decreased.
The drug diffusion from the film can be prolonged and followed zero order kinetics.
Incorporation of water soluble polymer PVP into the CA film decreased the tensile
strength of the film and increased film permeability, but did not alter the drug diffusion
kinetics.
1.4 Application of Plasticizers on Oral Solid Dosage Form
Plasticizers are typically low molecular weight compounds which are capable of
penetrating into the polymer structure and making them soft and flexible. The process of
adding a plasticizer or heat to soften the material and makes it more plastic is called
plasticization. The plasticization was applied in several of pharmaceutical process
including film preparation, hot melt extrusion and matrix tablet preparation to improve
the process condition or/and achieve better functionality.
The plasticization is occurred by the intermolecular interaction between the
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plasticizer and the polymer. This interaction increases the free volume between the
polymer chains and ease of movement of polymer chains could be dramatically
increased. Thus both of the glass transition temperature and the melting viscosity of the
polymer decreases after plasticization. The interaction of polymer and plasticizer also
help to lower the melting energy of the semi-crystalline polymers and facilitate the
fusion.
The purpose of incorporation of plasticizer into the film formulation is to improve
the mechanical properties and modify drug release behavior. The plasticizer typically
increases the elongation and elastic modulus of film. Addition of plasticizer can prompt
to film formation, reduce the brittleness, improve the flexibility and plasticity and
increase the mechanic resistance of the film. Lower water permeability and oxygen
transition rates were observed for plasticized film. The drug release rate from the film or
the film coated pellets can be modulated by the addition of the plasticizer. In general,
hydrophilic plasticizer accelerates the drug release and hydrophobic plasticizer
suppresses the drug release.
Application of the plasticizer in the hot-melt extrusion process often lowers the
process temperature and improves the process condition. With the help of the plasticizer,
a hot-melt extrusion process can be performed at lower temperatures to avoid the
decomposition of the drug and the polymer. Since the decreased viscosity of the polymer
can be obtained after addition of the plasticizer, less energy is required for the process
and the process condition is improved.
The application of the plasticizer in sustained release tablets has been reported by
several scientists. Hardy et al [68] studied the plasticizer effect on the compression
properties of an HPMC matrix tablet. Except for water soluble plasticizer propylene
glycol, addition of other plasticizers especially hydrophobic plasticizer decreased the
tensile strength of the tablets and increased elasticity of the tablets. Yuan et al [58]
admixed the plasticizer with CA to modify theophylline release from the hydrophobic
matrix tablet. The rate of release of theophylline decreased after addition of the
plasticizer TEC. Xiao [69] investigated the plasticizer effect on the sustained release
matrix tablets prepared by ethyl cellulose. It was found addition of the plasticizer
decreased porosity of the tablet, thus the drug release rate was also decreased. The slower
drug release rate was observed for the tablets prepared with more concentrated and
hydrophobic plasticizer.
As a plasticizer for pharmaceutical application, the following properties are
required:
a)
b)
b)
d)
e)

Good plasticization efficiency
Non toxic
Compatible with drug and polymer
Nonvolatile and stable in the storage condition
Regulatory acceptance
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The commonly used pharmaceutical plasticizers and their physicochemical
properties are listed in Table 1-3. They have been investigated as plasticizers in different
pharmaceutical processes to demonstrate a good interaction with the polymers and a good
safety profile.
1.5 Co-processed Excipients for Oral Solid Dosage Forms
1.5.1 Excipient for oral solid dosage form
All the oral solid dosage forms consist of active pharmaceutical ingredients (API)
and excipients. Historically, excipients has been viewed as merely inert additives and not
been given the credit for their effect on the finished pharmaceutical dosage form. But the
importance of the excipients has been realized in recent years. In fact, the fate of a drug
product can be determined by the functionality of the excipient. The major contributions
of excipient to the end product include: 1) improving the process condition during
manufacturing [70]; 2) improving the physicochemical properties of API and enhancing
the stability and bioavailability; 3) modulating the drug release characteristic in the body
and improve the patient acceptability; 4) facilitating administration; 5) aiding product
identification; 6) attributing to overall safety and effectiveness.
The tablet is the most preferred dosage form among all oral solid dosage forms.
This is due to the precise dosing, cost effective manufacturing and good patient
compliance. The principal excipients in a tablet formulation include filler, binder,
disintegrant, lubricant, glidant and coating material. In-depth knowledge of
physicochemical properties of excipients and numerous pharmaceutical tests are required
while selecting the right excipient for a tablet formulation. Excipients with multiple
functions leading to less complicated formulation as well as time and cost effectiveness
are more preferred to be selected by pharmaceutical formulators.
Tablets are manufactured by either granulation or direct compression. Direct
compression is simpler and less expensive process because multiple granulation
processes were avoided. But it has specific requirement for the properties of the raw
materials such as good flowability, good compactability, less segregation potential, low
lubricant sensitivity and good machineability in a high speed tablet press. For most of the
tablet formulations (70-80%), the concentration of the excipients are higher than the
active drug. Therefore, excipients play a major role for direct compression formulations
[6, 71]. In order to reduce the development process and get the product to the market
faster, there is an increasing demand for multi-functional excipients for direct
compression formulations.
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Table 1-3.
plasticizers

Physical and chemical properties of commonly used pharmaceutical

Plasticizers
Triethyl Citrate (TEC)
Acetyltriethyl Citrate (ATEC)
Tributyl Citrate (TBC)
Acetyltributyl Citrate (ATBC)
Dibutyl Sebacate (DBS)

Boiling point
(ºC)
288
294
322
326
345
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Water solubility
(g/100 ml) @ 25ºC
5.5
0.7
<0.1
<0.1
<0.1

Log P
1.493 ± 0.570
3.731 ± 0.641
4.681 ± 0.571
6.919 ± 0.641
5.975 ± 0.228

1.5.2 The source of new excipient
The improved functional excipients typically come from new chemical entities,
new grades of existing materials or a new combination of existing materials [10, 72].
Development of a new chemical entity is usually a high risk and large investment. It must
undergo a very long cycle with various stages of regulatory approval for assessment of
safety and toxicity [10, 71]. The approval of new excipients is even more complicated
than a new drug product. It is a very time and money consuming process. Successful new
grades of the existing excipients can be obtained by the chemical modification such as the
pregelatinized starch, croscarmellose, and crospovidone, or by particle engineering such
as spray dried lactose, Avicel ®101,102, 200 (Microcrystalline cellulose), Methocel®
DC (direct compressible HPMC). It has been a very successful approach for developing
new excipients over last three decades. But the extent of functional improvement is very
limited because of the restricted range of possible modification. A new combination of
the existing excipients is another good choice because most tablet formulations currently
consist of multiple excipients. A large number of excipient combinations are available for
improving the performance of the existing excipients. Two development processes of the
new combinations are typically involved. They are physical mixing and co-processing.
The most successful physically mixed excipient on the market is Opadry®. It is a preblended dry powder coating formulation. It combines polymer, plasticizer and pigment to
provide a one-step coating formula. Kollidon® SR is another example of a combination
of mixed excipients. It contains polyvinyl acetate and polyvinyl pyrrolidone at ratio 80:20
and is used for sustained release matrix tablets. The co-processed excipient is combined
at a subparticle level of excipients. This is much broader platform for improving the
functionality of the existing excipients and has gained more attention over the years.
1.5.3 Co-processed excipient
The International Pharmaceutical Excipients Council (IPEC) defines a coprocessed excipient as follows: “A co-processed excipient is a combination of two or
more compendial or non-compendial excipients designed to physically modify their
properties in a manner not achievable by simple physical mixing and without significant
chemical change” [72]. Co-processed excipients contain two or more excipients and
possess the performance advantages over the physical mixture. Not only improved
performance but also reduction of undesired properties of a single excipient can be
achieved by using co-processing. The co-processing excipients are typically produced by
the commercially available pharmaceutical manufacture processes, such as wet
granulation, dry granulation, spray drying and freeze drying. Spray drying is the most
commonly used method and it is very simple and effective. Most importantly, it can
incorporate one excipient into another excipients’ particle structure and provide desirable
physical advantages.
The typical process of developing a co-processed excipient includes the following
steps [73]: a) identify the functionality requirements and select the appropriate excipients;
b) determine the ratio of various excipients; c) select the suitable co-process method such
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as spray dry, wet granulation; d) optimize the preparation process; e) evaluate the
physicochemical properties and functionality of the co-processed excipient.
The particle properties of excipients such as particle size, particle size distribution,
powder porosity and surface roughness can be modified by co-processing, thus improve
the functionality of the excipients including improved flowability, better compactability
and reduced segregation potential. These improved properties of an excipient make it
more suitable for direct compression formulations. The major benefits of the excipients
received from the co-processing were summarized as [73]: a) lack of chemical change; b)
reducing the number of excipients in one formulation; c) improved physical mechanical
properties such as flowability and compactability; d) better dilution potential and less
segregation potential; e) less lubricant sensitivity.
There are several co-processed excipients for immediate release formulation
available on the market as listed in Table 1-4. The improved manufacturing efficiency
and reduced cost of the final drug product can be obtained by using these co-processed
excipients.
1.5.4 New excipients in sustained release application
A sustained release matrix tablet is the simplest and the most cost effective
delivery system for modulating the drug release behavior in the body. The market of
sustained release tablets keeps increasing every year, but the development of new
excipients is relatively slow. There are only two new sustained release excipients coming
to the market in the last few decades.
One is Methocel® DC which was developed by Dow Chemical. It is a new grade
of HPMC polymers customized for direct compression application. The DC grade of
HPMC can achieve better flowability without comprising the sustainability and
compactability by strictly controlling the particle size distribution [74]. The other one is
Kollidon® SR which developed by BASF. It is a physical mixture of polyvinyl acetate
and polyvinyl pyrrolidone at ratio 80:20. Kollidon® SR can be used for both granulation
and direct compression process. The water soluble components polyvinyl pyrrolidone can
gradually leaches out from the matrix during dissolution thereby modulating the drug
release from the hydrophobic matrix system [75].
Beside the commercial available excipients, Xiao [69] developed a co-processed
excipient consisting of ethyl cellulose, plasticizer and fillers by a wet granulation method.
This excipient showed good flowability and compactability and can be used for
preparation of a hydrophobic matrix tablet. But this hydrophobic matrix tablet is only
suitable for the drugs with low water solubility. For highly water soluble drug, a
compression coating has to be applied to obtain a desired in vitro release profile.
In our study, we have developed a co-processed sustained release excipient
utilizing a cellulose acetate with plasticizer and other filler via various preparation
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Table 1-4.

Commercial available co-processed excipients

Ingredients of
co-processed
excipients
Lactose,
Kollidon 30,
Kollidon CL

Trade name

Manufacturer

Improved functions

Ludipress

BASF

Mannitol,
Kollindon
CL,PVA

Ludiflash

BASF

Lactose,
Lactitol

Pharmatose
DCL 40

DMV

Lactose,
cellulose

Cellactose

Meggle

Lactose,
MCC

Microcelac

Meggle

MCC,
silica dioxide

Prosolv

JRS Pharma

MCC, Mannitol

Avicel HFE
102

FMC
Biopolymer

Avicel CE15
Avicel CL611

FMC
Biopolymer
FMC
Biopolymer

Low degree of
hygroscopicity, good
flowability, tablet hardness
independent of machine speed
Less hydroscopicity, directly
compressible, good flowability,
resulting hard tablet with lower
friability
Good flowability, high dilution
potential, lower water uptake at
high humidity
Highly compressible, good
mouth-feel, better tableting
at low cost
Good flowability and binding
properties, less lubricant
sensitivity
Better flow, tablet strength and
less lubricant sensitivity
Better tablettability at slower
tablet speed, less lubricant
sensitivity
Smoother ,creamier mouth feel,
less tooth-packing

Starch, Lactose

StarLac

Roquette

Good flowabililty and
compactability with rapid
disintegration time

Kollindon VA
64,
Plasdone S 630

Copovidone

BASF

Good flowability and binding
properties

MCC, Guar
gum
MCC, Na CMC

Sugar, dextrin

Di-Pac

Domino

MCC,
crospovidone,
HPMC

PanExcea
MHC300G

Avantor

Mannitol,
calcium silicate

PanExcea
MHC200G

Avantor
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Increase formulation stability

Good flowability, low
hygroscopicity, direct
compressible
Good flowability, compactability
with rapid disintegration for
immediate release tablet
Good flowability, compactability
with rapid disintegration for oral
disintegrating tablet

methods. This co-processed excipient is designed to be used for directly compressed
sustained release matrix formulation and is suitable for both water soluble and insoluble
drugs.
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Chapter 2. Preparation of Co-processed Plasticized Cellulose Acetate Excipient and
Evaluation of the Physical and Compaction Properties
2.1 Introduction
A significant growth of the oral drug delivery system market was observed over
the last decade. According to the GBI’s research, it will maintain an 11.3% annual
growth rate till 2016 [76]. A sustained release matrix tablet is one of the major
components in the oral drug delivery system. This is the simplest and the most cost
effective dosage form for modulating the drug release behavior in the body. The
manufacturing process for sustained matrix tablets is similar to that of traditional tablets.
The common preparation methods are wet granulation, dry granulation and direct
compression. Among these methods, the direct compression method is the simplest and
requires less unit processes. But it has specific requirements for the properties of the
powder such as flowability, compactability. For most of the tablet formulations (7080%), the concentration of the excipients are higher than the active drug. Therefore,
excipients play a major role for direct compression formulation [6, 71]. In order to reduce
the development process and get the product to the market faster, there is a market
demand for multi-functional excipients for direct compression formulation development
of sustained release matrix tablets.
The improved functional excipients typically come from new chemical entities,
new grades of existing materials or a new combination of existing materials [72].
Development of a new chemical entity is usually a high risk and large investment. It must
undergo various stages of regulatory approval for assessment of safety and toxicity [71]
which is a time and money consuming process. Successful new grades of the existing
excipients can be obtained by the chemical modification such as the pregelatinized starch,
croscarmellose, and crospovidone, or by particle engineering such as spray dried lactose,
Avicel ®101,102, 200 (Microcrystalline cellulose), Methocel® DC (direct compressible
HPMC). It has been a very successful approach for developing new excipient over last
three decades. But the extent of functional improvement is very limited because of the
restricted range of possible modification. A new combination of the existing excipients is
another good choice because most tablet formulations currently consist of multiple
excipients. A large number of excipient combinations are available for improving the
performance of the existing excipients. Two development processes of the new
combinations are typically involved. They are physical mixing and co-processing. The
most successful physically mixed excipient on the market is Opadry®. It is a pre-blended
dry powder coating formulation. It combines polymer, plasticizer and pigment to provide
a one-step coating formula. Kollidon® SR is another example of a combination of mixed
excipients. It contains polyvinyl acetate and polyvinyl pyrrolidone at ratio 80:20 and used
for sustained release matrix tablets. The co-processed excipient is combined at a
subparticle level of excipients. This is much broader platform for improving the
functionality of the existing excipients and has gained more attention over the years.
The International Pharmaceutical Excipients Council (IPEC) defines a co-
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processed excipient as follows: “A co-processed excipient is a combination of two or
more compendial or non-compendial excipients designed to physically modify their
properties in a manner not achievable by simple physical mixing and without significant
chemical change”. Co-processed excipient contains two or more excipients and possesses
the performance advantages over the physical mixture. Not only improved performance
but also reduction of undesired properties of a single excipient can be achieved by using
co-processing. The co-processing excipients are typically produced by the commercially
available pharmaceutical manufacture processes, such as wet granulation, dry
granulation, spray drying and freeze drying. Spray drying is the most commonly used
method and it is very simple and effective. Most importantly, it can incorporate one
excipient into another excipients’ particle structure and provide desirable physical
advantages.
Several co-processed excipients for immediate release formulation are available
on the market. The improved manufacturing efficiency and reduced cost of the final drug
product can be obtained by using the co-processed excipient. But there is no
commercially available co-processed excipient for sustained release matrix formulation.
In our study, we have developed a co-processed sustained release excipient utilizing a
hydrophobic polymer with plasticizer and other filler via various preparation methods.
This co-processed excipient is designed to be used for directly compressed sustained
release matrix formulation.
The hydrophobic polymer we selected in our study is cellulose acetate (CA). It is
an extensively used polymer in pharmaceutical applications. Because of the hydrophobic
nature and good film properties of the CA, it is potentially a good polymer candidate for
sustained release matrix tablets. Sustained release matrix tablets prepared by cellulose
acetate have been investigated by using direct compression or wet granulation methods
[58, 61]. The results show that for a sparingly soluble drug theophylline, a large amount
of CA was required to achieve the desired sustained release profile. It was difficult to
formulate a highly water soluble drug by using CA as the retarding agent. Some studies
concluded that CA is very sensitive to the solubility of the drug and it is not suitable for
retarding the release for highly water soluble drug.
The purpose of our study is to modify the physical characteristic of the CA by
using co-processing technique and increasing the ability of cellulose acetate for
controlling the drug release rate for drugs of varying solubility. This chapter is focused
on the preparation and physical characterization of this novel co-processed excipient.
2.2 Materials and Methods
2.2.1 Materials
Cellulose acetate with 39.8% acetyl content and 38 cp viscosity (CA 398-10 NF,
Eastman, Kingsport, TN) was used as the main polymer in this study. Triethyl citrate
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(TEC), acetyltriethyl citrate (ATEC), acetyltributyl citrate (ATBC) and dibutyl sebacate
(DBS) (Morflex Inc., Greensboro, NC) were used as plasticizers. Regular dicalcium
phosphate dihydrate (DCP, Rhodia Inc., Blue Island, IL) and milled dicalcium phosphate
dihydrate (milled DCP Innophos Inc., Cranbury, IL) were used as filler. Magnesium
stearate (Mallinckrodt, Paris, KY) was used as a lubricant.
2.2.2 Methods
2.2.2.1 Co-processed methods
Three different methods including heat treatment, wet granulation and spray
drying were investigated for preparing the co-processed excipients. The formulations of
the co-processed excipients were listed in Table 2-1. We selected ATEC as a hydrophilic
plasticizer in F1 and ATBC as a hydrophobic plasticizer in F2. For comparison, we also
prepared formulation F0 which doesn’t contain any plasticizer.
A heat treatment method is the simplest preparation method in this study. CA
was mixed with appropriate amount of plasticizer in a mortar and pestle. This mixture
was treated in the 100° C oven for 12 hours. The heat treated CA and plasticizer mixture
was further mixed with regular DCP in a twin shell blender (Patterson-Kelley Co, East
Stroudsburg, PA) for 3 minutes.
The wet granulation method was performed in a high shear granulator (Collete
MICROGRAL, Niro Inc., Columbia, MD). Appropriate quantities of CA were mixed
with the milled DCP at impeller speed 1000 rpm for 1 minute. The plasticizer was
dissolved into acetone-isopropyl alcohol (70:30, v/v) solution. The liquid mixture was
added to the powder bed by a peristaltic pump at speed of 20g/min. The liquid mixed
with the powder at impeller speed of 1000 rpm and chopper speed of 4000 rpm for 2
minute to obtain the wet mass. The wet mass was dried in an oven dryer at 60°C for 2
hours to remove the solvent. The dried granules were passed through a 20 mesh sieve to
remove the large agglomerates.
The spray drying method was performed at lab scaled mini spray dryer B295
(Buchi, Switzerland). CA was dissolved in acetone: isopropyl alcohol (50:50) solution at
the concentration of 3%. An appropriate amount of plasticizer was added in this solution.
The milled DCP was suspended in the solution using a magnetic stirrer. This suspension
was spray dried while stirring. Operation parameters are as following: Inlet temperature:
80°C; outlet temperature 36-50°C; aspirator: 60%; air volume: 40ml and pumping rate:
50%. The resulting powders were kept in vacuum oven at 60 °C for 12 hours to remove
the excess solvent and then compressed into the 13mm tablets under the compression
force of 0.3 metric ton by using the Carver press. The co-processed granules were
obtained by passing the large tablets through a 20 mesh sieve. In order to investigate the
effect of formulation factors on the physical properties of the co-processed excipient, the
formulations containing different plasticizers and different concentration of plasticizer
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Table 2-1.
methods

Formulations of the co-processed excipients for three preparation

Ingredients
CA 398-10 NF
ATBC
ATEC
DCP
Total

Percentage (%)
F0
F1
F2
20
20
20
0
0
10
0
10
0
80
70
70
100
100
100
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were prepared by spray dried method and listed in Tables 2-2 and 2-3.
2.2.2.2 Bulk density, tap density and Carr’s index evaluation
Fill the dry granules in a 50ml graduated cylinder to approximately 40ml, record
the weight and bulk volume. The cylinder was tapped on a tap device (Vankel Industrails,
Edison, NJ) for 100, 200, 300, 400 times until a constant volume was achieved. This
volume was recorded as the tap volume. The bulk density (g/ml) was calculated by
Equation 2-1. The tap density was calculated by Equation 2-2 and the Carr’s index was
calculated by Equation 2-3.
Bulk density= Weight of the sample (g)/ Bulk volume (ml)

(Eq. 2-1)

Tap density= Weight of the sample (g)/ Tap volume (ml)

(Eq. 2-2)

Carr’s index=100*(Tap density-Bulk density)/ Tap density

(Eq. 2-3)

2.2.2.3 Powder porosity evaluation
The true density of the powder was measured by a helium pycnometer (AccuPyc
1330, Micromeritics, Norcross, GA). Powder porosity was calculated from the Equation
2-4.
Powder porosity (%) = (1 - bulk density/true density)*100

(Eq. 2-4)

2.2.2.4 Particle size analysis
The particle size distribution was evaluated by sieve analysis. This experiment
was performed on the Gilsonic Autosiever (Gilson Company Inc, Lewis Center, Ohio) for
7 minutes at amplitude of 5mm. The mesh size of the sieve used in this study were
20(850μm), 35 (500 μm), 60 (250 μm), 80 (180 μm), 120(125 μm), 140(106 μm) and
200(75 μm). Approximately 10g of granules was used for analysis. The geometric mean
particle size was calculated by Equation 2-5.
Dgw = log–1 [(Σ (Wi *log Di)/ ΣWi]

(Eq. 2-5)

where Dgw is the geometric mean particle size, Wi is the weight of the granules stayed on
the i th sieve, Di is the diameter of the i th sieve in the stack.
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Table 2-2.
plasticizers

Formulations of the co-processed excipients prepared from different

Ingredients
CA 398-10 NF
ATEC
ATBC
TEC
DBS
Milled DCP
Total

Percentage (%)
F1
F2
F3
20
20
20
10
0
0
0
10
0
0
0
10
0
0
0
70
70
70
100
100
100

F0
20
0
0
0
0
70
100

F4
20
0
0
0
10
70
100

Table 2-3.
Formulations of the co-processed excipients prepared from different
concentration of plasticizers
Ingredients
CA 398-10 NF
ATBC
Milled DCP
Total

Percentage (%)
F2
F5
20
20
10
2.5
70
77.5
100
100

F0
20
0
80
100

28

F6
20
5
75
100

2.2.2.5 Powder flowability evaluation
In order to provide an overall evaluation of the powder flowability, a weighted
composite index was used [77]. It can be calculated by Equation 2-6. The three
parameters (critical orifice, Carr’s index and angle of repose) in this equation all
contribute to 1/3 of the overall flowability. The highest value of the composite index is
100. If the value is greater than 70, the sample can be considered to have a good
flowability. Carr’s index was calculated by Equation 2-3. Critical orifice was measured
by using a Flowdex (Hanson Research, Chatsworth, CA) and the angle of repose was
measured by funnel method.
Composite index = -10/9*critical orifice +340/9 + (- 2/3*Carr’s Index)
+110/3+ (-2/3* angle of repose) +50
(Eq. 2-6)
2.2.2.6 Specific surface area measurement
Specific surface area of all the batches was determined by the nitrogen gas
adsorption method. The weighed sample was first degassed at 40°C under nitrogen gas to
remove moisture and contamination. The surface area of the degassed sample was
measured by the Gemini Surface Analyzer (Micromeritics, Norcross, GA) using nitrogen
gas as absorption gas source. The multipoint BET (Brunauer, Emmett and Teller)
equation was used for calculation.
2.2.2.7 Scanning electron microscopy (SEM) study
SEM was used to characterize the powder morphology. The powders were first
coated by 10nm gold on the surface for improving the conductivity, and then were
examined by the FEI XL-30 Scanning Electron Microscopy. (FEI, Hillsboro, OR).
2.2.2.8 Compactability evaluation
The compactability of the co-processed excipients was evaluated by the
compression profile and the Heckel plot. The co-processed excipient was first mixed
with 0.5% magnesium stearate in a twin shell blender (Patterson-Kelley Co, East
Stroudsburg, PA) for 2 minutes, and then was compressed into 400 mg tablets at
compression forces of 0.3, 0.5, 0.8, 1.0, and 1.5 metric ton by using a 3/8 inch flat faced
tooling on a Carver press (Carver Inc., Wabash, IN) . The dwell time was maintaining 3
seconds for all the batches. Five tablets were prepared for each batch. Hardness of the
resulting tablet was measured by a PTB 311 hardness tester (PharmaTest, Germany). The
tensile strength of tablets was calculated from the Equation 2-7.
Tensile strength=2*hardness/πDl
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(Eq. 2-7)

where D is the tablet diameter and l is the tablet thickness.
The Heckel’s plot [78, 79] for the co-processed excipient was constructed by the
Equation 2-8.
ln(1/(1 − D)) = kP + A

(Eq. 2-8)

where D is the relative density of a powder column at pressure P, k is the slope. A is a
constant. The slope of the Heckel’s equation can be used to calculate the yield strength as
Equation 2-9.
Y = 1/ k

(Eq. 2-9)

The lower yield strength indicates less amount energy is required for plastic
deformation.
2.2.2.9 Glass transition temperature (Tg) measurement
A cast film method was used to prepare film samples. CA 398-10 NF was
dissolved into acetone solution at a concentration of 10%. Appropriate amount of
plasticizer was added to the solution and mixed uniformly with the 10 % CA solution.
Thereafter, 1ml of the solution was transferred to a Teflon Petri dish and dried at 60°C in
vacuum oven for 24 hours to remove the solvent. The Differential Scanning Calorimeters
(DSC) (TA instruments, New Castle, Delaware) was used to determine the Tg of the film.
Conventional modulate DSC program was employed in this study. The heating rate is 20
°C/ min and the heating range is 30°C to 220°C. The TA Universal V 4.4A software was
used to analyze the data.
2.3 Results and Discussion
2.3.1 Effect of different process methods
2.3.1.1 Morphology
The SEM image of the raw material as well as the co-processed excipients was
shown in Figure 2-1. Since the images of F0, F1 and F2 for each process method are
similar, we only selected F2 as an example. The original CA has the irregular particle
shape and the rough surface. After it mixed with the plasticizer ATBC and heated for 12
hours in the oven, as shown in Figure 2-1B, the particle shape and the surface structure
remained similar to the original CA. This indicates the plasticizer is only physically
adsorbed on the surface of CA or penetrates into the small pores in the CA particles.
Strong interaction between the polymer and the plasticizer was not observed. For the wet
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Figure 2-1. SEM image of the excipient
A: Original cellulose acetate 398-10 NF; B: CA mixed with ATBC at 2:1 ratio and heat
treated for 12hours; C: milled Dicalcium phosphate; D: co-processed F2 granules by
using wet granulation method; E: spray dried powder of F2 formulation; F: dry granules
of spray dried F2.

31

granulation process, the starting materials are milled DCP and CA mixture, the milled
DCP exhibit a long prism crystalline structure under the SEM. These crystalline
substances agglomerated with the CA particles after the wet granulation. The crystalline
structure remains the same at the final granules as shown in Figure 2-1D. The original
CA particle in the agglomerate is hard to identify because of the interaction with wet
agent which contains the plasticizer during wet granulation. The CA particles dissolved
or partially dissolved in the wetting agent and formed the liquid bridges which remain
between the solid particles. This liquid bridge will be solidified once particles are dried.
The original shape and surface of CA particles were changed and a new shape and
surface were generated. Figure 2-1E showed the spray dried mixture of CA, milled DCP
and plasticizer. In this mixture, CA was presented as a film form. These films remained
on the surface of the milled DCP or in an individual small piece. The plasticizer
completely interacted with CA and remained inside the CA film. The crystalline structure
of DCP was totally covered by the plasticized CA film. The particle size of the spray
dried powder was increased after dry granulation, but the film form of plasticized CA did
not change in the agglomerate as shown in Figure 2-1E.
2.3.1.2 The physical characteristics
The physical properties of the co-processed excipients are influenced by the
preparation methods as shown in Table 2-4. For the excipients prepared by the heat
treatment method, the three formulations exhibit similar bulk density, tap density and the
mean particle size. The only physical difference was observed from the powder porosity.
The two formulations with plasticizer showed lower porosity than the formulation
without plasticizer. This is because the plasticizer only remained on the polymer surface
and did not change the size and surface of the polymer as illustrated in Figure 2-1B. The
porosity decrease is due to the liquid plasticizer which filled the pores of the polymer
powder. For the excipients prepared by wet granulation method, addition of the
plasticizer decreases the bulk density, taps density and increases the powder porosity.
These differences can be explained by two factors. Firstly, the interaction of the
plasticizer and polymer results in a stronger and smoother film, therefore less particle
interlock appears in the processed excipient. Secondly, the density of liquid plasticizer is
less than the solid DCP. This contributes to a lower bulk density and tap density. The
excipients prepared by the spray dried methods showed similar physical properties. This
process method is very powerful and totally changed the physical properties of the
original polymer. The resulting new physical form was not affected by the addition of the
plasticizer and the type of the plasticizer. Among the three preparation methods, the heat
treatment method and wet granulation method generate more density and less porous
excipients and the spray dried method generates light and porous excipients. The particle
size of the excipients prepared by spray dried method and wet granulation method are
larger than the heat treatment method. This is because the agglomerates formed in those
two processes.
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Table 2-4.
Physical properties for the co-processed excipient prepared by three
different methods
Geometric

Bulk
density
(g/ml)

Tap
density
(g/ml)

Carr’s
index
(%)

porosity
(%)

particle
size ( µm)

F0 (Heat treatment)

0.67

F1 (Heat treatment)
F2(Heat treatment)
F0(Wet granulation)
F1(Wet granulation)
F2(Wet granulation)
F0(Spray dried)
F1(Spray dried)
F2(Spray dried)

0.66
0.67
0.77
0.68
0.63

0.79
0.80

15.75
14.78
17.74
18.61
12.88
13.54
21.11
23.42
22.00

69.16
65.93
65.04
63.50
67.11
68.46
73.88
73.40
72.60

196.34
204.51
205.85
299.82
277.54
287.71
249.36
261.44
247.16

Formulations

0.52
0.55
0.54

0.82
0.88
0.79
0.77
0.68
0.73
0.69
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Powder

mean

2.3.1.3 Flow characteristics
The flowability of the co-processed excipients is listed in Table 2-5. All the coprocessed excipients prepared in this study showed good flowability, the flowability
composite index all greater than 70. The flowability results suggested that the flowability
of the co-processed excipients was only affected by the preparation method and that the
formulation factors including addition of plasticizer and the type of plasticizer did not
affect the powder flowability. The excipients prepared by heat treatment method and wet
granulation method showed better flowability than the spray dried method. The large
amount of fine powders existing in spray dried excipients as shown in Figure 2-1E is
responsible for the smaller flowability index.
2.3.1.4 Compactability
2.3.1.4.1 Compression profile
The compression profile of all the co-processed excipients was shown in
Figure 2-2. The co-processed excipients prepared by spray dried method exhibit the best
compactability and form the strongest tablets. Followed by the wet granulation method,
poor mechanical strength was observed from the tablets prepared from the heat treatment
co-processed excipients. Even at highest compression pressure, the tensile strength of
both formulation F1 and F2 are smaller than 1.0. This poor mechanical strength may
result in tablet breakage during rigorous handling and transportation. In all the
preparation methods, addition of the plasticizer decreased the tensile strength of the
tablets due to the soften effect of the plasticizer on the polymer. The type ATEC produces
stronger tablets than the hydrophobic plasticizer ATBC for all three preparation methods.
The compactability difference can be explained by the surface area results (Table 2-6).
For plastic deformation material CA, it will only undergo plastic deformation and won’t
generate new surface during compression. The tensile strength of final tablet is directly
related to the surface area of the material. The bigger surface area of the material, the
more chance for the particles connect to each other to form solid bonding and yield
stronger tablet. In our study, we found the linear relationship between the surface area
and the tensile strength of the tablets at the compression force of 1.5m ton. (R2=0.94)
Typically, plasticizer can penetrate to the polymer structure and make the polymer more
flexible and have better mobility. Therefore, the smoother surface will be expected when
we mix plasticizer with the polymer. The smooth surface has less surface area compare to
the irregular surface. If the plasticizer doesn’t interact very well with the polymer, only
one part of the plasticizer molecules enters the polymer structure and other part remains
outside of the polymer structure, the surface area of the polymer will even less because
the excess liquid filled all the void space of the surface. The surface area results indicate
the plasticizer ATEC has a better interaction with CA than ATBC. This result was
consistence with the result of glass transition temperature. In this study, the co-processed
excipient prepared by spray dried method exhibit high powder porosity and large surface
area. Without the plasticizer, the wet granulated excipient has similar surface area to the
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Table 2-5.
Flow properties for the co-processed excipient prepared by three
different methods
Formulations
F0 (Heat treatment)
F1 (Heat treatment)
F2(Heat treatment)
F0(Wet granulation)
F1(Wet granulation)
F2(Wet granulation)
F0(Spray dried)
F1(Spray dried)
F2(Spray dried)

Carr’s
index
(%)
15.75
14.78
17.74
18.61
13.54
12.88
21.11
23.42
22.00

Critical
orifice
(mm)
5
5
5
4
4
4
12
12
12
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Angle of
repose
(degree)
26.77
26.48
27.56
26.48
26.01
26.19
26.00
27.70
27.60

Flowability
composite
Index
90.54
91.38
88.69
89.94
93.63
93.95
79.70
77.04
78.05

6

F0 (Heat
treatment)

Tensile strength (MPa)

5

F1 (Heat
treatment)
F2(Heat
treatment)

4

F0 (Wet
granulation)

3

F1 (Wet
granulation)
2

F2(Wet
granulation)
F0 (Spray dried)

1

F1 (Spray dried)
0
0

50

100

150

Compression
pressure (MPa)

200

250

F2(Spray dried)

Figure 2-2. Compression profile of the co-processed excipients prepared by three
different methods
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Table 2-6.
Specific surface area of the co-processed excipients prepared by three
different methods
Specific surface area (m2/g)
2.0001±0.053
0.2831±0.015
0.1618±0.044
2.3176±0.032
0.8545±0.009
0.5860±0.008
7.7629±0.005
3.5017±0.064
2.7999±0.042

Formulations
F0 (Heat treatment)
F1 (Heat treatment)
F2 (Heat treatment)
F0 (Wet granulation)
F1(Wet granulation)
F2(Wet granulation)
F0(Spray dried)
F1(Spray dried)
F2(Spray dried)
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heat treated excipient. After addition of the plasticizer, the heat treated excipient showed
less surface area than the wet granulated excipient for both formulations F1 and F2. This
indicated the better interaction between the polymer and the plasticizer in wet granulation
process.
2.3.1.4.2 Heckel’s plot
Heckel’s plot results (Figure 2-3) show that addition of plasticizer decreases the
yield strength of the co-processed excipients for all preparation methods and the type of
the plasticizer did not significantly affect the yield strength. This result suggests the
plasticized excipients can deform easier than unplasticized excipient under compression
force. All of the co-processed excipients formulations contain 70-80% DCP. DCP is a
typical brittle material and will undergo fragmental deformation during compression. It
doesn’t have the plastic properties and the slope of Heckel’s plot is close to zero. When
DCP mixed with the plastic material CA, the mixture showed certain plastic properties,
but the slope is still very small and requires more energy for deformation. A plasticizer
will add plasticity to the powder mixture and less energy is required for the plasticized
mixture. In our study, we also found that preparation methods affect the yield strength.
The order for the yield strength of the co-processed excipients is: spray dried< wet
granulation< heat treatment. The possible explanation could be: a) the interaction
between the plasticizer and CA: the spray dried method provides the best interaction and
the least interaction during the heat treatment method; b) the surface area: the larger
surface exposed to the compression force, the more area available for deformation and
easier plastic deformation can be expected.
2.3.2 Effect of formulation factors
2.3.2.1 Physical characteristic
The physical properties of the co-processed excipients prepared from different
plasticizers and different concentrations of plasticizer were listed in Tables 2-7 and 2-8.
All the formulations listed in Tables 2-7 and 2-8 exhibits very similar physical
properties. This indicates the process method played a major role in controlling the
physical properties of the co-processed excipients. The formulation factors have less
influence on the physical properties of the final excipients.
2.3.2.2 Flow characteristic
Similar results were observed for flow characteristic as shown in Tables 2-9 and
2-10. All of the formulations prepared by the spray dried method showed similar flow
properties. The flow characteristic of the granules is directly related to the shape and size
of the granules. Because all of the formulations showed the similar density, particle size
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F0 (Heat treatment)
Y=460.29
2

F1 (Heat treatment)
Y=428.04
F2(Heat treatment)
Y=392.03

Ln (1-1/D)
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F0 (Wet granulation)
Y=395.18
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F1 (Wet granulation)
Y=292.56
F2(Wet granulation)
Y=320.16
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F0 (Spray dried) Y=358.24
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F1 (Spray dried)Y=236.84
F2(Spray dried) Y=229.87

1
0

50

100

150

200

250

Compression pressure (MPa)

Figure 2-3. Heckel’s plot of the co-processed excipients prepared by three
different methods
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Table 2-7.
Physical properties for the co-processed excipients prepared from
different plasticizers by using spray dried method

Formulations
F0 (no plasticizer)
F1(ATEC)
F2(ATBC)
F3(TEC)
F4(DBS)

Bulk
density
(g/ml)

Tap
density
(g/ml)

Carr’s
index
(%)

Powder
porosity
(%)

0.52
0.55
0.54
0.54
0.55

0.68
0.73
0.69
0.67
0.73

21.11
23.42
22.00
18.35
25.44

73.88
73.40
72.60
71.32
71.39

Geometric
mean
particle
size ( µm)
249.36
261.44
247.16
267.94
278.92

Table 2-8.
Physical properties for the co-processed excipients prepared from
different concentrations of plasticizer by using spray dried method
Formulations
F0(no plasticizer)
F5(2.5%ATBC)
F6(5% ATBC)

F2(10%ATBC)

Bulk
density
(g/ml)
0.52
0.52
0.53
0.54

Tap
density
(g/ml)
0.68
0.67
0.66
0.69
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Carr’s
index
(%)
21.11
22.16
18.97
22.00

Powder
porosity
(%)
73.88
74.07
73.35
72.60

Geometric
mean particle
size ( µm)
249.36
257.36
247.50
247.16

Table 2-9.
Flow properties for the co-processed excipient prepared by different
plasticizers by using spray dried method

Formulations
F0(no plasticizer)
F5(2.5%ATBC)
F6(5% ATBC)
F2(10%ATBC)

Carr’s
index (%)

Critical
orifice(mm)

Angle of repose
(degree)

21.11
22.16
18.97
22.00

12

26.00

Flowability
composite
index
79.70

12
12

27.76
27.07

77.83
80.42

12

27.60

78.05

Table 2-10. Flow properties for the co-processed excipient prepared by different
concentrations of plasticizer by using spray dried method
Formulations
F0 (no plasticizer)
F1 (ATEC)
F2 (ATBC)
F3 (TEC)
F4 (DBS)

Carr’s
index (%)

Critical
orifice(mm)

Angle of repose
(degree)

21.11
23.42
22.00
18.35
25.44

12
12
12
14
14

26.00
27.70
27.60
30.48
27.36
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Flowability
composite
index
79.70
77.04
78.05
76.34
73.69

distribution and particle shape, the similar flow properties can be expected. The
flowability index for the formulations is greater than 70, which suggest the good
flowability of the granules and suitable for direct compression.
2.3.2.3 Compactability
2.3.2.3.1 Compression profile
The compression profile of the co-processed excipients was affected by the type
of plasticizers and the concentrations of plasticizer as shown in Figures 2-4 and 2-5. The
tensile strength was decreased after addition of different type of plasticizers. The tablets
containing the most hydrophilic plasticizer TEC showed the highest tensile strength, the
lowest tensile strength was observed for tablets containing plasticizer DBS. The reasons
of the tensile strength difference caused by the type of plasticizer can be explained by the
hydrophobicity of the plasticizer and the interaction of plasticizer with CA. Based on the
Log P value, the hydrophobicity of plasticizers used in this study is:
ATBC>DBS>ATEC>TEC. The hydrophobic plasticizer is prone to contribute to the
hydrogen bonding between the solid particles, therefore better mechanical strength. For
the plasticizers with similar hydrophobicity, the interaction of the plasticizer with CA
played a role. The interaction of the plasticizer with CA can be assessed by the glass
transition temperature of CA. The glass transition temperature result is shown in
Figure 2-6. Four plasticizers used in this study all can decrease the glass transition
temperature of CA. The most effective plasticizer is ATEC which showed lowest glass
transition temperature. The order of glass transition temperature of the plasticized CA is
ATEC < TEC < ATBC< DBS. For the least effective plasticizer DBS, there is little
interaction with the polymer and phase separation will take place during compression.
The extra liquid available between the solid particles will affect the formation of solid
bonding. The significant decrease of the tensile strength was observed.
The effect of plasticizer concentration on the compression profile was
demonstrated in Figure 2-5. When the concentration of plasticizer is below 5%, addition
of the plasticizer increases the tensile strength of the tablets. But when the concentration
of plasticizer climbs to 10%, the presence of plasticizer decreases the mechanical strength
of the tablets. The similar phenomenon was observed when compressing MCC with a
small amount of water as plasticizer and compressing HPMC with a small amount of
water as plasticizer [5, 80]. In their study [80], it was found that bonding area increased
after adding the plasticizer. But upon increasing the plasticizer concentration, the bonding
strength is much reduced due to the softening effect of the plasticizer on the polymer.
This effect is stronger than the effect of increasing the bonding area. This explained the
effect of plasticizer concentration on the tensile strength of tablets.
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Figure 2-4. Compression profile of the co-processed excipients prepared from
different plasticizers by using spray dried method
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Figure 2-5. Compression profile of the co-processed excipients prepared from
different concentrations of plasticizer by using spray dried method
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Figure 2-6.

Glass transition temperature of CA with different plasticizers
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2.3.2.3.2 Heckel’s plot
The effect of plasticizers on Heckel’s plot is demonstrated in Figure 2-7. All the
plasticizers used in this study lower the yield strength. The type of plasticizer did not
affect the yield strength of co-processed excipients, but the concentration of plasticizer
affects the plasticity of the co-processed excipients. As shown in Figure 2-8, the yield
strength of the co-processed excipient is decreased when increasing the plasticizer
concentration. This suggests increased plasticity of the co-processed excipient with high
concentration of plasticizer.
2.4 Conclusions
The co-processed excipients with CA, plasticizer and inert excipient were
successfully prepared by using three different methods. The physical, flow and
compaction properties of the co-processed excipients were influenced by the formulation
factors as well as the process methods. We found the physical and flow properties are
controlled by the process methods and the formulation factors have less impact.
The co-processed excipients prepared in this study all showed good flow
characteristic. The flowability of heat treated and wet granulated co-processed excipients
are better than the spray dried excipients. The compactability of the co-processed
excipients is affected by both process methods and formulation factors. The spray dried
process produced more porous particles with larger surface area. These particles required
the least energy for plastic deformation during compression and formed the tablets with
highest mechanical strength. The wet granulated excipients showed moderate plastic
deformation capacity and resulting tablets with acceptable tensile strength. The heat
treated excipients required more energy to deform under compression pressure than the
other two methods. The resulting tablets have poor mechanical property.
For all preparation methods, addition of 10% plasticizer increases the plasticity of
the final excipient and decreases the tablet tensile strength. The tablets containing
hydrophilic plasticizer showed better tensile strength than the hydrophobic plasticizer.
The increased interaction between the plasticizer and the polymer also results in tablets
with better tensile strength. The concentration of plasticizer also affects the
compactability of the co-processed excipient. The tensile strength of the tablets increased
at low plasticizer concentration and the reverse effect was observed on higher plasticizer
concentration. Based on results obtained from the study, both wet granulated and spray
dried excipients showed desired flowability and acceptable compactability. All of them
appear to be satisfactory excipient candidates for direct compression formulation, but the
controlled release capacity of these excipients needs to be investigated.
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Figure 2-7. Heckel’s plot of the co-processed excipients prepared from different
plasticizers by using spray dried method
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Figure 2-8. Heckel’s plot of the co-processed excipients prepared from different
concentrations of plasticizer by using spray dried method
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Chapter 3. Sustained Release Properties and Drug Release Mechanism Study of a
Novel Co-processed Excipient
3.1 Introduction
The co-processed plasticized cellulose acetate with inert excipients was
successfully developed by three different methods as described in chapter two. Those coprocessed excipients showed good flowability, acceptable compactability and suitability
for direct compression.
In this chapter, we investigated the sustained release properties of the novel coprocessed excipients and the factors which can affect the drug release from the matrix
tablets. The drug release mechanism for the matrix tablets was also studied by using two
empirical mathematic equations. A freely water soluble drug propranolol hydrochloride
was selected as the model drug to study the drug release characteristics from the matrices.
The sparingly water soluble drug theophylline and water insoluble drug flurbiprofen were
used to evaluate the drug solubility effect on the dissolution profile.
3.2 Materials and Methods
3.2.1 Materials
Cellulose acetate with 39.8% acetyl content and 38 cp viscosities (CA 398-10 NF,
Eastman, Kingsport, TN) was used as the main polymer in this study. Triethyl citrate
(TEC), acetyltriethyl citrate (ATEC), acetyltributyl citrate (ATBC) and dibutyl sebacate
(DBS) (Morflex Inc., Greensboro, NC) were used as plasticizers. Regular dicalcium
phosphate dihydrate (DCP, Rhodia Inc., Blue Island, IL) and milled dicalcium phosphate
dihydrate (milled DCP Innophos Inc., Cranbury, IL) were used as filler. Magnesium
stearate (Mallinckrodt, Paris, KY) was used as a lubricant. Propranolol hydrochloride was
used as water soluble model drug, Theophylline anhydrous (BASF, Ludwigshafen,
Germany) was used as sparingly water soluble drug and flurbiprofen (Sun Pharma,
Maharashtra, India) was used as a water insoluble drug.
3.2.2 Methods
3.2.2.1 Tablets preparation
For comparison purpose, the tablets containing different concentrations of
unprocessed CA were prepared by a direct compression method. The formulations are
listed in Table 3-1. Tablets were compressed on a Carver Press (Carver Inc., Wabash,
IN) by using 3/8 inch flat face punch at 1.5 metric ton compression force. The dwell time
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Table 3-1.

Formulations of the tablets prepared from the unprocessed CA

Ingredients
Propranolol hydrochloride
CA 398-10 NF
Regular DCP
Magnesium stearate
Total

Percentage (%)
A2
20
30
49.5
0.5
100

A1
20
15
64.5
0.5
100

50

A3
20
50
29.5
0.5
100

is 3 seconds and the target weight is 400mg.
Tablets containing the co-processed excipient were also prepared by direct
compression method. All the tablets prepared by the co-processed excipients share the
same formula. All the tablets contain 20% drug, 79.5% co-processed excipient and 0.5%
magnesium stearate. The ingredients were mixed by passing through a 20 mesh sieve 3
times and then compressed into 400mg tablets at the same compression condition as the
unprocessed CA tablets. In order to investigate the compression force effect, two
additional compression forces 0.5 m ton and 1.0m ton also applied.
3.2.2.2 In vitro dissolution study
The USP Apparatus II (Hanson SR-8 Plus, Hanson Research Corporation,
Chatsworth, CA) was used to evaluate the drug release. Three tablets from each batch
were tested. 900 ml of distilled water, pH 7.4 phosphate buffer and pH 7.2 phosphate
buffer at 37 ± 0.5°C was used as the dissolution medium for evaluate the release of
propranolol hydrochloride, theophylline and flurobiprofen respectively. The samples
were taken at predetermined time points for 12 hours. The absorbance of the solution was
measured at 289 nm, 274nm and 277nm respectively by a UV-spectrophotometer
(Perkin-Elmer Corporation, Norwalk, CT). The drug concentration and the percentage of
drug release were calculated by the software DissLab®.
In order to determine the pH effect on dissolution profile, 900ml simulated gastric
fluid (without enzymes) and simulated intestine fluid (without enzymes) were used as
dissolution medium. The tablets prepared by mixing propranolol hydrochloride and spray
dried co-processed excipient F2 for evaluation. The drug dissolution profile was
compared by using f2 value as described in Equation 3-1.
2 -0.5

f2 =50×log{[1+(1+1/n) ∑t=1 (Rt -Tt ) ]

×100}

(Eq. 3-1)

where f2 is a similarity factor, n is the number of sample times, Rt is the average
percentage of drug released at time t for the reference sample, Tt is the average
percentage of drug released at time t for the test sample. According to FDA’s guidance
for industry, if f2 values were greater than 50, the two dissolution profiles can be consider
as similar or equivalent.
3.2.2.3 Tablet porosity measurement
The true density (ρt) of the lubricated drug and co-processed excipients mixture
were determined by a helium pycnometer (AccuPyc 1330, Micromeritics, Norcross, GA).
The density of the tablet (ρa) was calculated from Equation 3-2.
ρa = π* r2* l
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(Eq. 3-2)

where r is the radial of the tablet and l is the thickness of the tablet.
The porosities of the tablets (ε) were calculated from the tablet density (ρa) and
true density (ρt) of the mixture using the following Equation 3-3:
ε = 100 (1- ρa/ρt)

(Eq. 3-3)

3.2.2.4 Tablet surface examination
The surface of tablets was first coated by 10nm gold particles for improving the
conductivity. The morphology of the tablets surface was examined by the FEI XL-30
Scannig Electron Microscopy. (SEM, FEI, Hillsboro, OR)
3.2.2.5 Initial water penetration study
The initial water penetration study of the tablets was performed in a 0.1%
methylene blue solution. Tablets was first dipped into this solution for 1 minute, then
taken out, wiped the excess liquid and cut into half to observe the surface and the cross
section under the Olympus MIC-D microscope. (Olympus, Center Valley, PA).
3.2.2.6 Drug solubility measurement
The excess amount of drug was put in the corresponding dissolution medium,
then vortexed for 3 minutes. The mixture was shaken for 7 days at 37°C to reach
equilibrium. The sample was taken and centrifuged at 10000 rpm for 10 minutes. The
supernatant was filtered by a 0.45µm membrane filter. The filtrate was diluted by the
dissolution medium and the concentration of the dilution was determined by UVSpectrophotometer (Perkin-Elmer Corporation, Norwalk, CT).
3.2.2.7 Drug release mechanism study
Drug-release mechanism was studied by fitting the dissolution data to two
empirical mathematical equations including Higuchi equation and power law.
The Higuchi equation was developed in 1961 [11, 36] to describe the drug release
from the inert matrix tablets. The equation is as following:
Qt =

S2 Dε
τ

1
2

1

2C0 -εCS CS t =kt2

(Eq. 3-4)

where Qt is the cumulative amount of drug released over a surface unit in time t; S is the
surface area of the tablet; D denotes the drug diffusion coefficient in the matrix phase; Cs
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is the drug solubility in the matrix; C0 represents the drug concentration in the matrix; ε is
the porosity; τ denotes the tortuosity of the matrix; and k is the dissolution rate constant.
Based on this equation, drug release at any given time is proportional to the
square root of the time. The release rate constant k can be calculated from the dissolution
profile. Dε/τ (effective diffusion coefficient) also can be calculated from the constant k
and known drug and tablet properties.
The general equation of the power law [45] is Equation 3-5.

Mt/ M∞=k*tn

(Eq. 3-5)

where Mt is cumulative amount of drug released at time t, M∞ is cumulative amount of
drug released at infinite time; k is release constant incorporating structural and geometric
characteristics of the system, and n is the release exponent indicating the mechanism of
drug release.
The release exponent ‘n’ in the power law takes multiple values based on
geometry of the system. For a cylinder shape tablets, if n<0.45, the major release
mechanism is Fickian diffusion; if the n value >0.89, Case-II transport in which the
polymer relaxation is the rate limiting process; if n value between 0.45 and 0.89, the
“anomalous transport” takes place where both of drug diffusion and swelling of the
polymer are involved.
Addition to model fit, the geometric dimension of the tablets prepared with drugs
of different solubility was measured before and after the dissolution by using the caliper.
3.3 Results and Discussion
3.3.1 Dissolution profile of unprocessed CA
The previous research on CA for matrix tablet polymer demonstrated that the CA
matrices are sensitive to the solubility of the drug [61]. As a retarding agent, it not
suitable for controlling the release for freely water soluble drug from the matrix tablet.
Our study showed in Figure 3-1 has an agreement with results from the literature. When
the concentration of CA is 15% and 30%, more than ninety percent drug released within
1 hour. Even the concentration of CA reaches to 50%, eighty percent of drug released
within 2.5 hours. Because of the low bulk density of CA (0.289g/ml), the mixtures with
higher concentration of CA exceeded the volume limitation of the die. Tablet with higher
concentrations of CA was not prepared in this study. These results confirmed that the
unprocessed CA could not be used to formulate the sustained release matrix tablets for
freely water soluble drug at concentrations less than 50%.
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Figure 3-1.

Dissolution profile of the tablets containing unprocessed CA
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3.3.2 The effect of preparation process of co-processed excipients on drug release
3.3.2.1 Dissolution profile
The dissolution profile (Figure 3-2) shows that drug release characteristic was
directly related to the preparation process and formulation factors of the co-processed
excipients. All the tablets prepared from the heat treatment co-processed excipient have a
rapid dissolution rate. More than 90% drug was released in the first hour. The tablets
prepared from the wet granulated co-processed excipients show slower drug release rate.
The slowest drug release rate was obtained from the tablets prepared from spray dried coprocessed excipient. For the co-processed excipients prepared from wet granulation
method and spray dried method, addition of the plasticizer significantly decreased the
drug release rate and the hydrophobic plasticizer ATBC demonstrated slower release rate
than the hydrophilic plasticizer ATEC. Since the spray dried excipients provided the
slowest sustained release profile among these three methods, it was selected for further
investigation. The difference in drug release profiles can be explained by tablet porosity,
tablet surface morphology and initial water penetration rate as discussed below.
3.3.2.2 Tablet porosity
For a hydrophobic matrix tablet, irregular pores will be formed during
compression due to the boundaries of the particles. For this system, drug release must be
preceded by the drug dissolution in medium filled pores and by diffusion through
medium filled channels. The size, structure and amount of the pores are very important
for controlling the drug release [81].
The porosity of the tablets is listed in Table 3-2. For all the co-processed
excipient, despite of the preparation method, addition of plasticizer significantly
decreases the porosity of the tablets (p<0.05). Fewer diffusion channels will be presented
due to the decreased porosity. Therefore, the slower drug release profile was observed for
the plasticized matrices than the unplasticized matrices. But the type of the plasticizer and
the excipient preparation methods did not significantly affect the porosity of the tablets
(p>0.05). Even though there is a clear dissolution difference among the tablets with
different co-processed excipients, we could attribute the difference in porosity of the
tablets alone. This result suggests the overall porosity is not the only factor which has
influence on the drug dissolution. Other factors such as hydrophobicity, size and
tortuosity are also expected to play an important role in controlling the drug release from
the matrix system.
3.3.2.3 Tablet surface morphology
Figure 3-3 showed the surface morphology of the tablets prepared from coprocessed excipient formula F2 with 20% propranolol hydrochloride. The surface of the
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Figure 3-2. Dissolution profile of tablets containing the co-processed excipients
prepared from different process methods
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Table 3-2.
Porosity of the tablets prepared by propranolol hydrochloride and
different co-processed excipients
Preparation of coprocessed excipients
Heat treatment
Wet granulation
Spray drying

F0
17.06±1.00
17.30±1.34
16.95±1.48
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Porosity (%)
F1
10.12±1.60
10.68±0.72
9.37±0.65

F2
10.77±0.54
10.92±1.25
9.53±0.85

A

B

C

Figure 3-3. SEM of tablet surface
A: Tablet containing 20% propranolol and 79.5% heat treated excipient F2; B: tablet
containing 20% propranolol and 79.5% wet granulated excipient F2; C: tablet containing
20% propranolol and 79.5% spray dried excipient F2.
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tablets prepared from the heat treatment excipient showed several big cracks, these cracks
can act as channels for water penetration and drug diffusion, therefore resulting faster
drug release. Small cracks were observed on the surface of the tablet prepared from the
wet granulated excipient. A smooth and film-like surface was observed from the tablet
prepared from the spray dried excipient. The small and individual pores were presented
uniformly in the entire surface. This uniform structure can effectively reduce the water
penetration and result in a prolonged drug release. These observations reveal the surface
characteristics and the effect of pore structure on water penetration and can be used for
explaining the dissolution differences among the preparation methods of co-processed
excipients. This finding is in good agreement with the literature [61].
3.3.2.4 Initial water penetration study
Initial water penetration results are shown in Figure 3-4. The rapid initial water
penetration rate was found in the tablet prepared from the heat treatment excipient. Water
penetrates the whole body of the tablet within 1 minute. For the wet granulated excipient,
the surface of tablet showed a broken film structure, water penetrated through the broken
parts of the film. The water penetrated to 1/3 of the tablet within 1 minute. The slowest
initial water penetration rate was obtained from the tablet prepared by spray dried coprocessed excipient. Water stayed primarily on the surface of the tablet and the body of
the tablet appeared dry. This confirmed the finding from the tablet surface morphology
study. The film-like surface structure prevents the water penetration thereby decreasing
the drug release rate.
3.3.3 The effect of co-processed excipients’ formulation on drug release
3.3.3.1 The effect of the type of plasticizer
The drug release rate was decreased while increasing the logP value of plasticizer
as illustrated on Figure 3-5. Since the similar porosity results was obtained for the
tablets prepared by different plasticizers as shown in Table 3-3. The hydrophobicity of
plasticizer plays a role for controlling the drug release. For hydrophilic plasticizers TEC
and ATEC, they have some solubility in the water. They will dissolve in the water while
in contact with the aqueous dissolution medium and leave the pores for water penetration
and drug diffusion resulting in a rapid dissolution rate. DBS and ATBC are hydrophobic
and practically insoluble in the water. The rate of these two hydrophobic plasticizers
leaving the matrices is much slower than those two hydrophilic plasticizers. According to
the glass transition temperature of CA with different plasticizers (Figure 2-4), ATBC has
the better interaction with the CA compare to DBS. Therefore, ATBC remains in the
matrices longer than DBS. Thus the slowest drug release rate was observed for the tablets
containing ATBC as a plasticizer.
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Figure 3-4. Initial water penetration study
A: Surface of tablet containing 20% propranolol and 79.5% heat treated excipient F2; B:
cross-section of tablet containing 20% propranolol and 79.5% heat treated excipient F2;
C: surface of tablet containing 20% propranolol and 79.5% wet granulated excipient F2;
D:tablets containing 20% propranolol and 79.5% spray dried excipient F2.
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Figure 3-5. The effect of the type of plasticizer of co-processed excipient on the
drug release
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Table 3-3.
Porosity of tablets prepared by propranolol hydrochloride and coprocessed excipients with different plasticizers
Formulations
F0(no plasticizer)
F1(ATEC)
F2(ATBC)
F3(TEC)
F4(DBS)

Porosity (%)
16.95±1.48
9.37±0.65
9.53±0.85
10.05±0.88
10.66±1.76
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3.3.3.2 The effect of plasticizer concentration
Figure 3-6 demonstrates the concentration of plasticizer has a strong impact on
the drug release rate. The drug dissolution rate was decreased with increasing
hydrophobic plasticizer concentration. According to the Heckel’s plot result (Figure 2-7),
the plasticity of the granules was also increased with increasing concentration of
plasticizer. Granules with better plasticity form more solid bonding during compression
and lead to harder tablet at the same compression pressures. Therefore significant
reduction of tablet porosity (p<0.05) was observed as shown in Table 3-4, also showing a
difference in drug dissolution profile.
3.3.4 The effect of compression force on drug dissolution
One common feature of the hydrophobic matrix tablet is the compression force
effect on drug dissolution. Tablets compressed at high compression force result in less
volume and lower porosity. As a consequence, the drug release rate will be slower at the
higher compression force. This phenomenon was observed in different hydrophobic
matrix systems. In our study, the compression force effect on drug dissolution profile was
investigated on the tablets containing 20% drug propranolol hydrochloride and spray
dried co-processed excipient F2. The result is shown in Figure 3-7. It is evident that drug
release rate decreased as compression force increased. The porosity of the tablets as
shown in Table 3-5 confirmed the porosity decreased as the compression force increased.
These results show typical hydrophobic matrix tablet behavior when using this novel coprocessed excipient as a retarding agent.
3.3.5 pH effect of dissolution medium on drug dissolution profile
In our study, CA is a pH-independent polymer. It remains insoluble in GI tract
(pH 1.2-7.4). The model drug propranolol hydrochloride is a hydrochloride salt with pka
9.5. When the pH ranges from 1.2 to 7.4, it shows a pH independent solubility profile.
The result of pH effect on drug dissolution was shown in Figure 3-8. The drug release
rate in three different medium are very close to each other. We used the dissolution
profile of water as reference, the f2 value of the simulated gastric fluid (SGF) is 71.2 and
the simulated intestinal fluid (SIF) is 95.7. The f2 results suggest the three dissolution
profiles are similar. Based on this result, we can conclude this novel co-processed
excipient can provide a pH independent dissolution profile for a pH insensitive drug.
However, for a pH sensitive drug, the dissolution profile is expected to vary under
different pH conditions as the solubility of the drug changes.
3.3.6 Drug solubility effect on drug dissolution profile
Three drugs with different water solubility were selected in this study. The drug
solubility in respect to the dissolution medium were tested and listed in Table 3-6. Based
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Figure 3-6. The effect of plasticizer concentration of co-processed excipient on the
drug release
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Table 3-4.
Porosity of tablets prepared by propranolol and co-processed
excipients with different concentration of ATBC
Porosity (%)

Formulations
F0(no plasticizer)
F5(2.5%ATBC)
F6(5% ATBC)
F2(10%ATBC)

16.95±1.48
15.63±1.06
12.35±0.84
9.53±0.85
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Compression force effect on drug release
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Table 3-5.
Porosity of tablets prepared by propranolol and spray dried excipient
F2 at different compression force
Compression force
0.5 m ton
1.0 m ton
1.5 m ton

Porosity (%)
14.63±1.26
10.97±0.63
9.53±0.85
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Figure 3-8.

pH effect on drug release profile
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Table 3-6.

Solubility of different drugs in dissolution medium at 37°C

Drug
Propranolol hydrochloride
Theophylline anhydrous
Flurbiprofen

Dissolution medium
DI water
pH 7.4 phosphate buffer
pH 7.2 phosphate buffer
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Solubility (mg/ml)
192.79±1.93
11.19±0.18
4.52±0.07

on the solubility result, propranolol hydrochloride was used as a freely water soluble
drug; theophylline anhydrous was used as sparingly soluble drug and flurbiprofen was
used as water insoluble drug. The solubility effect on drug dissolution profile was
illustrated in Figure 3-9. For all the co-processed excipients selected in this study, the
drug with higher solubility always show faster release rate. For the same drug, the order
of the release rate is F0> F1> F2. This order is valid for all three drugs. This result
indicates the plasticized co-processed excipient has better control release ability than the
unplasticized co-processed excipient. However, the difference of the drug release rate
between the plasticized excipient and unplasticized excipient for three drugs is not the
same. The freely soluble drug propranolol hydrochloride exhibits a large difference (more
than 40% release difference in 12hours) in dissolution profile between the plasticized
formulation and unplasticized formulation. While there is a small amount decrease (less
than 10% release difference in 12hours) of plasticized formulation for the water insoluble
drug flurbiprofen was observed. This result suggests the plasticizer effect has more
impact when utilized on a water soluble drug.
3.3.7 Drug release mechanism study
3.3.7.1 Higuchi model
The Higuchi model was used to plot the drug release profile of the tablets with
three different drugs and two different spray dried co-processed excipients. The results
were displayed in Figures 3-10 and 3-11. All six formulations showed a good fit (R2
>0.98) for the Higuchi model. This indicates the drug release from the novel coprocessed excipient matrix follows square root kinetics. The constant K which is the
slope in the Higuchi equation represents the drug release rate. A higher K value was
observed for unplasticized matrices (F0) in spite of the solubility of the drug. The drug
with higher solubility also showed a higher K value for both plasticized and unplasticized
matrices.
Typically, two factors are responsible for reducing the drug diffusion coefficient
in the matrix. One is the porosity factor ε. Since the drug cannot cross the solid matrix,
the void space available for drug diffusion is reduced by 1/ε. Another is tortuosity factor
τ. The pores structure in the matrix does not tend to be straight and the drug need to travel
longer distance in order to diffuse. The diffusion coefficient is reduced by the increasing
path length which is a tortuosity factor τ. The effective diffusion coefficient from the
matrix considered both factors and is defined as:
Deff = Dε/τ

(Eq. 3-6)

where Deff is the effective diffusion coefficient; D is diffusion coefficient. According the
Higuchi equation, after we know the K, Cs, C0 and ε, Deff can be calculated. Deff describes
the real situation for drug diffusion from the matrix [82].
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Drug solubility effect on dissolution profile
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Figure 3-10. Higuchi model fitting for tablets prepared from co-processed
excipient F0
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Figure 3-11. Higuchi model fitting for tablets prepared from the co-processed
excipient F2
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The Deff for six different matrices was calculated and listed in Table 3-7. For all
three drugs, the Deff in an unplasticized matrix (F0) is higher than in a plasticized matrix
(F2). This indicates the presence of the plasticizer can help to prevent the drug diffusion
from the matrix.
3.3.7.2 Power law model
The same six dissolution profiles were fitted to the logarithmic transformed power
law equation. The results were illustrated in Figures 3-12 and 3-13. The n value which is
the slope of logarithm transformed power law equation indicates the drug release
mechanism. For all the tablets prepared by the spray dried co-processed excipients F2, n
values for all drugs are less or close to 0.45. This suggests drug release is controlled by
Fickian diffusion. For the tablets prepared by the spray dried co-processed excipient F0, n
values for water insoluble drug flurbiprofen and sparingly water soluble drug
theophylline are less or close to 0.45. But n value for water soluble drug propranolol
hydrochloride is 0.621, which suggests both drug diffusion and matrix relaxation take
place.
For the hydrophobic matrix tablet, the tablet will remain intact after dissolution.
Since the polymer CA is water insoluble and does not hydrate in the water, the size
change of matrix tablet during dissolution was not expected. Table 3-8 listed the tablet
size change after the dissolution. Except for the tablet containing propranolol
hydrochloride and spray dried F0, other tablets all maintained the similar size after
dissolution. This confirmed with the result of the power law equation that tablet
relaxation did not contribute significantly to the drug release. For the tablet comprising
freely water soluble drug and unplasticized excipient, a 13.35% increase in thickness was
observed. The picture taken after dissolution (Figure 3-14B) showed the several cracks
in the body of tablet. This cracks can shorten the drug diffusion pathway, therefore
increase the drug release rate. These cracks also contribute to the matrix relaxation
mechanism. Because we did not observe the matrix relaxation in other 5 formulations, it
can be concluded this is not caused by the polymer relaxation. The possible reason maybe
the high osmotic pressure generated by the freely water soluble drug propranolol
hydrochloride affected the tablet structure and caused the resulting cracks. However for
the tablet prepared with propranolol hydrochloride and plasticized co-processed excipient
F2 the plasticized tablet is more robust and can withstand the osmotic pressure and the
tablet structure can be maintained. For the water soluble drug, the plasticizer can
maintain tablet shape during dissolution, therefore prolonging the drug release.
3.4 Conclusions
The spray dried co-processed excipients successfully controlled the release of a
freely water soluble drug from a matrix tablet. It demonstrated a slower drug release
profile than the co-excipients prepared by the other two processing methods. The surface
morphology and initial water penetration study found the spray dried co-processed
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Table 3-7.
Higuchi release constant and effective diffusion coefficient for
different drugs in different matrices
Formulations
Propranolol (F0)
Theophylline (F0)
Flurbiprofen (F0)
Propranolol (F2)
Theophylline (F2)
Flurbiprofen (F2)

K value
13.47
5.0973
3.4642
5.4992
3.3455
2.7234
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Deff
0.00739
0.014697
0.016688
0.001108
0.006296
0.010293
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Figure 3-12. Power law model fitting for tablets prepared from the co-processed
excipient F0
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Figure 3-13. Power law model fitting for tablets prepared from the co-processed
excipient F2
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Table 3-8.

Tablet size change after dissolution

Formulations
Propranolol (F0)
Theophylline (F0)
Flurbiprofen (F0)
Propranolol (F2)
Theophylline (F2)
Flurbiprofen (F2)

Diameter change (%)
2.65±0.3
1.57±1.31
2.09±1.23
0.18±0.32
0.10±0.10
0.76±0.26
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Thickness change(%)
13.35±0.43
0.66±0.01
0.29±0.21
0.28±0.57
0.66±0.16
0.19±0.42

A

B

Figure 3-14. Pictures of tablet containing 20% propranolol hydrochloride and
spray dried excipient F0
A: Before dissolution; B: after 12hours dissolution.
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excipient can form the continuous film liked structure on the tablet surface which can
effectively prevent water penetration and drug diffusion. The drug release rate from the
matrix tablets containing the novel spray dried excipients can be decreased by increasing
the hydrophobicity of the plasticizer and plasticizer concentration. The drug release rate
from the matrix was affected by the compression force but not the pH of the dissolution
medium. The drug release from the matrix tablet can be described by Higuchi equation
and the power law equation. Based on porosity results and drug release mechanism study,
addition of plasticizer to the co-processed excipients showed decrease in the drug release
rate is due to three reasons: a) decrease in the porosity of the tablet; b) decrease in the
effective diffusion coefficient; c) assist in maintaining tablet structure during dissolution.
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Chapter 4. Hydrophilic Polymer Effect on the Plasticized Cellulose Acetate Matrix
Tablets
4.1 Introduction
For a highly water soluble drug, the use of hydrophilic polymer alone for
controlling the drug release from the matrix is restricted due to the rapid diffusion
through the gel layer. For such drugs, hydrophobic polymers are suitable as retarding
agents. The hydrophobic polymers can offer several advantages including good stability
at varying pH and resistant to the environmental moisture [2, 17, 19] However, for a
simple monolithic hydrophobic matrix, an increase of the diffusion pathway and a
decrease of the effective diffusion area as a function of time often results in incomplete
release within the gastrointestinal transit time. To modulate drug release, it may be
necessary to incorporate soluble ingredients such as lactose or PEG into formulation. The
presence of soluble ingredient in the formulations helps to form numerous pores in
hydrophobic matrix network for water penetration and drug diffusion. Therefore,
complete drug release can be obtained from the highly porous matrix [44]. But burst
release is a potential risk when an excessive amount of water soluble ingredient is present
in the hydrophobic matrix. The hydrophilic nature of these pore formers can result the
rapid surface erosion and cause fast surface drug release initially.
In this chapter, we developed a swellable porous matrix tablet by incorporating a
small amount of hydrophilic polymer into the hydrophobic matrix. The swelling property
of the hydrophilic polymer during dissolution is utilized to generate highly porous
structure in the hydrophobic matrix for obtaining complete drug release. The initial
viscous gel formation of the hydrophilic polymer upon contacting with water also can
help to suppress the burst release of the drug. The effect of the type of hydrophilic
polymer, the concentration of hydrophilic polymer, the viscosity of hydrophilic polymer
and the particle size of hydrophilic polymer on drug release and the drug release
mechanism from this novel system was investigated in this chapter.
4.2 Materials and Methods
4.2.1 Materials
Cellulose acetate with 39.8% acetyl content and 38 cp viscosity (CA 398-10 NF,
Eastman, Kingsport, TN) was used as the main polymer in this study. Triethyl citrate
(TEC), acetyltriethyl citrate (ATEC), acetyltributyl citrate (ATBC) and dibutyl sebacate
(DBS) (Morflex Inc., Greensboro, NC) were used as plasticizers. Milled dicalcium
phosphate dihydrate (milled DCP Innophos Inc., Cranbury, IL) was used as filler.
Magnesium stearate (Mallinckrodt, Paris, KY) was used as a lubricant. Spray dried
lactose monohydrate (Lactose 316, Foremost, Baraboo, WI) and partially pregelatinized
corn starch (Starch® 1500, Colorcon, West point, PA) were used as pore former for
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hydrophobic matrix tablet. Propranolol hydrochloride was used as a water soluble model
drug. Five different viscosity grades (E5, E50, K100 CR, K4M CR and K100M CR) of
hydroxypropyl methylcellulose (HPMC, Dow Chemical Company, Midland MI), the
highest viscosity grade of hydroxypropyl cellulose (HPC HXF, Asland, Covington, KY),
hydroxyethyl cellulose (HEC HHX, Asland, Covington, KY) and polyethylene oxide
(Polyox® 303, Dow Chemical, Midland MI) were selected as hydrophilic polymer.
Methylene blue (JT Baker, Phillipsburg, NJ) and FD&C orange (Opatint PG, Colorcon,
West point, PA) were used as dye to indicate the different components in the tablets.
4.2.2 Methods
4.2.2.1 Tablets preparation
The tablet formulations were listed in Tables 4-1 to 4-6. The tablets were
prepared by direct compression method. All the ingredients were mixed by passing
through 20 mesh sieve 3 times. The mixtures were compressed on a Carver Press (Carver
Inc., Wabash, IN) by 3/8 inch flat face punch at 1.5 metric ton compression force. The
dwell time is 3 seconds and the target weight is 400mg.
4.2.2.2 In vitro dissolution study
The USP Apparatus II (Hanson SR-8 Plus, Hanson Research Corporation,
Chatsworth, CA) was used to evaluate the drug release. Three tablets from each batch
were tested. 900 ml of distilled water at 37 ± 0.5°C was used as the dissolution medium
for evaluate the release of propranolol hydrochloride. The samples were taken at
predetermined time points for 12 hours. The absorbance of the solution was measured at
289 nm by a UV-spectrophotometer (Perkin-Elmer Corporation, Norwalk, CT). The drug
concentration and the percentage of drug release were calculated by the software
DissLab®.
The difference of drug dissolution profiles was evaluated by using f2 value as
described in Equation 4-1 [24].
2 -0.5

f2 =50×log{[1+(1+1/n) ∑t=1 (Rt -Tt ) ]

×100}

(Eq. 4-1)

where f2 is a similarity factor, n is the number of sample times, Rt is the average
percentage of drug released at time t for the reference sample, Tt is the average
percentage of drug released at time t for the test sample. According to FDA’s guidance
for industry, if f2 values were greater than 50, the two dissolution profiles can be consider
as similar or equivalent.
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Table 4-1.

Formulations for tablets prepared with different type of pore formers

Ingredients
Propranolol hydrochloride
Spray dried excipient F2
Polyox® 303
Lactose 316
Starch® 1500
Magnesium Stearate
Total

Percentage (%)
H2
P1
20
20
74.5
74.5
5
0
0
5
0
0
0.5
0.5
100
100

H0
20
79.5
0
0
0
0.5
100

P2
20
74.5
0
0
5
0.5
100

Table 4-2.
Formulations for tablets prepared with different concentrations of
hydrophilic polymer
Ingredients
Propranolol hydrochloride
Spray dried excipient F2
Polyox® 303
Magnesium Stearate
Total

Percentage (%)
H1
H2
20
20
77
74.5
2.5
5
0.5
0.5
100
100

H0
20
79.5
0
0.5
100
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H3
20
69.5
10
0.5
100

Table 4-3.

Formulations for tablets prepared with different hydrophilic polymers

Ingredients
Propranolol hydrochloride
Spray dried excipient F2
Polyox® 303
HPMC K100M CR
HPC HXF
HEC HHX
Magnesium Stearate
Total

Percentage (%)
H4
H5
20
20
74.5
74.5
0
0
5
0
0
5
0
0
0.5
0.5
100
100

H2
20
74.5
5
0
0
0
0.5
100

H6
20
74.5
0
0
0
5
0.5
100

Table 4-4.
Formulations for tablets prepared with different viscosity grades of
hydrophilic polymer
Ingredients
Propranolol hydrochloride
Spray dried excipient F2
HPMC E5
HPMC E50
HPMC K100LV
HPMC K4M
HPMC K100M
Magnesium Stearate
Total

H7
20
74.5
5
0
0
0
0
0.5
100

Percentage (%)
H8
H9
H10
20
20
20
74.5
74.5
74.5
0
0
0
5
0
0
0
5
0
0
0
5
0
0
0
0.5
0.5
0.5
100
100
100
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H4
20
74.5
0
0
0
0
5
0.5
100

Table 4-5.
Formulations for tablets prepared with different co-processed
excipients and hydrophilic polymer Polyox 303
Ingredients
Propranolol hydrochloride
Spray dried excipient F2
Polyox® 303 (20-60mesh)
Polyox® 303 (60-140mesh)
Polyox® 303 (<140mesh)
Magnesium Stearate
Total

H2A
20
74.5
5
0
0
0.5
100

Percentage (%)
H2B
20
74.5
0
5
0
0.5
100

H2C
20
74.5
0
0
5
0.5
100

Table 4-6.
Formulations for tablets prepared with different co-processed
excipients and hydrophilic polymer Polyox 303
Ingredients
Propranolol hydrochloride
Spray dried excipient F0
Spray dried excipient F1
Spray dried excipient F2
Polyox® 303
Magnesium Stearate
Total

H11
20
74.5
0
0
5
0.5
100
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Percentage (%)
H12
20
0
74.5
0
5
0.5
100

H2
20
0
0
74.5
5
0.5
100

4.2.2.3 Optical microscopic examination
In order to identify different components of tablet during dissolution, the colored
tablets were prepared. An appropriate amount of methylene blue was added to the coprocessed excipient formulation in 0.1% concentration. The methylene blue was
processed along with the other excipient as the same condition. The final co-processed
excipient appeared a dark blue color. An appropriate amount of FD&C orange dye was
dispersed in the isopropanol alcohol, and then mixed with Polyox® 303. The wet mass
was kept in 40°C oven overnight to remove the solvent. The dried particles were passed
through 20 mesh sieve to obtain orange color Polyox® 303. The colored tablets were
prepared by blue co-processed excipient F2, orange Polyox® 303, white model drug
propranolol hydrochloride and lubricant as the same concentration and same preparation
procedure as the formulation H0 and H2. These colored tablets were placed in the same
dissolution condition as the normal tablets for 1, 6 and 12 hours, and then took it out to
observe the surface and cross-section under the Olympus MIC-D microscope. (Olympus,
Center Valley, PA). The geometric dimension of the tablets was measured by using the
caliper.
4.2.2.4 Mathematic model fitting
4.2.2.4.1 Power law equation
Drug-release mechanism was first studied by fitting the dissolution data to the
power law equation [45].
Mt/ M∞=k*tn

(Eq. 4-2)

where Mt is cumulative amount of drug released at time t, M∞ is cumulative amount of
drug released at infinite time; k is release constant incorporating structural and geometric
characteristics of the system, and n is the release exponent indicating the mechanism of
drug release.
The release exponent ‘n’ in the power law takes multiple values based on
geometry of the system. For a cylinder shape tablets, if n<0.45, the major release
mechanism is Fickian diffusion; if the n value >0.89, Case-II transport in which the
polymer relaxation is the rate limiting process; if n value between 0.45 and 0.89, the
“anomalous transport” takes place where both of drug diffusion and swelling of the
polymer are involved.
4.2.2.4.2 Peppas and Shalin equation
Peppas and Shalin equation [50] is a modification of power law equation. It was
performed by decoupling diffusion and “Case-II transport” with the following expression:
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Mt/ M∞=k1*tm + k2*t2m

(Eq. 4-3)

where k1 and k2 are the release constants and m is the pure Fickian diffusion exponent.
The exponent m is related to the aspect ratio of the tablets. . For the aspect ratio of tablet
around 3, the m value is 0.45. And m=0.45 was used in our study. The first term in the
right hand of the Equation 4-3 represents the contribution of Fickian diffusion (F) and
the second term represents the contribution of tablet structure relaxation (R). R/F ratio
can be calculated using Equation 4-4:
R/F = k2*tm/k1

(Eq. 4-4)

The dominant drug release mechanism can be determined by the R/F ratio at any
given time during dissolution. The model fit was performed by the software GraphPad
Prism 4.
4.3 Results and Discussion
4.3.1 The effect of different pore formers on drug dissolution
Incompletely release is a common problem associated with the hydrophobic
matrix tablet. The typical solution is to add water soluble pore formers such as lactose
and PEG to the matrix. The water soluble ingredient in the matrix will dissolve during
dissolution and the pores will be formed in the matrix after the soluble material leached
out. Those pores can act as the channels for water penetration and drug diffusion,
therefore help to increase the drug release at the final stage. In our study, we selected
three different pore formers. There are lactose, Starch 1500 and Polyox® 303. Lactose is
a traditional pore former and easily dissolves in the water. Starch 1500 is a partially
gelatinized starch and it is not soluble in the water. But it will expand after absorbing the
dissolution medium thus pores or cracks will be created in tablet structure. Polyox® 303
is a water soluble polymer. It has swelling property and can form a viscous gel upon
contact with dissolution medium. The gel will be eroded during dissolution and leave
empty space in the matrix for drug diffusion. The effect of the three pore formers on the
drug release was shown in Figure 4-1. Compared to the formulation without any pore
former (H0), all the pore formers used in our study significantly increased the drug
release at 12 hours (P<0.05). Due to the swelling property of Starch® 1500 and Polyox®
303, the swollen tablets with large amount of water filled pores and cracks were observed
after dissolution for both formulations P2 and H2.The complete drug release (>90%) at
12 hours was also observed for those two formulations. For formulation P1 which
contains lactose as pore former, the external tablet size remained the same as original
during dissolution. The drug release at 12 hours for P1 was only 78.59±0.40%. This
indicates the pores generated inside are not sufficient for complete drug release. The
impact of the pore formers on drug release was exhibited not only on the final stage but
also on the initial stage. A significant burst release at the first hour was observed for both
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Figure 4-1.

The effect of the pore formers on drug dissolution
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formulation P1 and P2. This can be explained by the hydrophilic nature of lactose and
Starch 1500. They can facilitate the surface erosion of the tablet resulting rapid surface
drug release. Formulation H2 which contains Polyox® 303 as the pore former showed
limited burst release at first hour. The first hour release of formulation H2 is similar as
the formulation H0 without any pore former. Even though Polyox® 303 also has a
hydrophilic nature, the initial viscous gel formation helped to prevent the rapid burst
release. The viscous gel formation counterbalanced the hydrophilic nature of Polyox®
303 Therefore a similar release rate during the first hour for formulation H0 and H2 was
observed.
4.3.2 The effect of the concentration of hydrophilic polymer on drug dissolution
The concentration effect of the hydrophilic polymer was illustrated in Figure 4-2.
Compared to the formulation without any hydrophilic polymer, addition of the
hydrophilic polymer significantly increased the drug release at 12 hours (P<0.05). The
addition of hydrophilic polymer has less influence on the initial drug release. The
decreased drug release rate only took place on 0.25 hour while 0.5 hour and 1.0 hour
remained similar (P>0.05). When the concentration of the hydrophilic polymer is in the
range of 0-5%, the drug release rate increased with increasing hydrophilic polymer
concentration. Once the concentration of hydrophilic reached 5%, further increasing the
concentration of hydrophilic polymer to 10% did not change the drug release rate. This
indicates the limit amount of the hydrophilic polymer that is required for improving the
final drug release and an excess amount of hydrophilic polymer will not further
contribute to modulating the drug release profile within these ranges.
4.3.3 The type of hydrophilic polymer effect on drug dissolution
Cellulose derivatives are most commonly used hydrophilic polymers in
development of hydrophilic matrix tablets. To exclude the pH effect of the system, we
selected three pH independent cellulose derivatives with similar viscosity but different
substitution. These were HEC HHX, HPMC 100KM CR and HPC HXF. According to
the chemical structure difference, the rank of hydrophilicity is HEC> HPMC> HPC. Due
to the difference of the hydrophilicity, these polymers have different erosion and swelling
behavior. It was demonstrated that those polymers exhibited different sustained release
behavior as the hydrophilic matrix tablets were developed. In addition to the cellulose
derivatives, another commonly used pH independent hydrophilic polymer polyethylene
oxide (Polyox® 303) was chosen. It is a hydrophilic polymer with relatively fast swelling
and erosion rate. The type of hydrophilic polymer effect on the drug release was shown in
Figure 4-3. Only formulation H5 prepared with the most hydrophobic polymer HPC
showed slightly slower drug release at the final stage. The other dissolution curves are
very close to each other. The f2 value was used for comparison of these four dissolution
profiles. We selected formulation H2 as reference, the f2 values for H4, H5 and H6 are
64.09, 69.65 and 74.99 respectively. This result suggests the type of hydrophilic polymer
has less impact on the drug release in this matrix system.
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4.3.4 The effect of hydrophilic polymer viscosity grades on drug dissolution
The viscosity grade of hydrophilic polymer is a major factor on controlling the
drug release from the hydrophilic matrix system. In order to discover the effect of
viscosity of hydrophilic polymer on drug release from the plastic inert matrix system, five
different viscosity grades of HPMC were selected. The five grades of HPMC included
two low viscosity grades E5 and E50, one middle viscosity grade 100 LV, two high
viscosity grades K4M and K100M. For the hydrophilic polymer with low viscosity, it
could not be used alone for prepare the hydrophilic matrix tablets due to the less strength
of gel layer and rapid erosion of tablets [2]. The result of polymer viscosity effect was
demonstrated in Figure 4-4. Initially, the drug release rate slightly decreased with an
increase in viscosity of hydrophilic polymer. The drug release decrease at the first hour is
not statistically significant between formulations containing E5 and E50 (P>0.05), but
statistically significant between formulations containing E5 and K100, K4M or K100M
(P<0.05). There is no statistical difference on drug release at the first hour among the
formulations containing K100 LV, K4M and K100M. At the final stage, the viscosity of
the polymer effect is opposite to the initial stage. Drug release increased as an increase in
the viscosity of the hydrophilic polymer. The significant drug release increase (P<0.05) at
12 hours was observed while increase the polymer viscosity from E5 to K100 LV.
Further increase the polymer viscosity from K100 LV to K100M, the increase in drug
release at 12 hours was not significant (P>0.05). This result can be explained by the
insufficient swellability and less gel strength of the low viscosity grades of HPMC. Low
viscosity grades HPMC formed weak gel layer initially then result rapid surface release
and. insufficient swellability of low viscosity grades HPMC could not generate large size
of pores for water penetration and drug diffusion then result incomplete release finally.
From Figure 4-4, we also found that the middle to high viscosity grades polymer behave
similar in terms of modulating the drug release from the plastic matrix system. We took
formulation prepared with K100 M as a reference, f2 values for formulations prepared
with K4M and K100 are 79.78 and 86.43 respectively. This may be due to two reasons:
1) the swellability of the hydrophilic polymer with higher viscosity was restricted by the
hydrophobic matrix network; 2) the fast erosion rate of the middle viscosity grade
hydrophilic polymer result drug leaches out from the matrix.
4.3.5 The particle size of hydrophilic polymer effect on drug dissolution
The particle size of the hydrophilic polymer is another factor which affects the
drug release from the hydrophilic matrix system. The hydrophilic polymer with large
particle size often exhibits slower hydration rate and result fast drug release. Three
fractions of Polyox® 303 were selected to study the particle size effect on the drug
release from this matrix system. The result was shown in Figure 4-5. Three dissolution
profiles are almost overlapped in this picture. This suggests the particle size of this
hydrophilic polymer did not affect the drug release from this matrix system. This also
indicates the drug release was not sensitive to the hydration rate of the hydrophilic
polymer.
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4.3.6 The effect of formulation factors of co-processed excipient on drug dissolution
Three different co-processed excipients prepared by spray dried method were
selected. The hydrophilic polymer Polyox® 303 was fixed at 5% for all formulations in
the matrix. Figure 4-6 showed the effect of the co-processed excipient on drug
dissolution. The tablets prepared by the unplasticized co-processed excipient F0 showed
rapid drug release, more than 80% drug released at 6 hours. These tablets could not
maintain their shape during the dissolution. All the tablets fall apart after dissolution.
The unplasticized matrix could not withstand the stretch of the tablet. The rigid and
brittle bond was broken by the swell of the hydrophilic polymer. On the contrast, the
plasticized matrix tablets H2 (ATBC as plasticizer) and H12 (ATEC as plasticizer) all
swollen but still kept intact at the end of dissolution. This can be explained by the
plasticizer effect. The plasticizer contributes to the flexibility and elongation of the tablet
matrix therefore help to maintain the integrity of the tablet. As shown in Figure 4-6, the
tablets prepared with co-processed excipient F1 (ATEC as plasticizer) showed similar
dissolution profile as the tablets prepared with co-processed excipient F2 (ATBC as
plasticizer). The similarity factor f2 value of these two dissolution profile is 77.78. This
indicates the type of the plasticizer in co-processed excipient has less impact on drug
release from this matrix system.
4.3.7 The effect of pH of dissolution medium on drug dissolution
The model drug propranolol hydrochloride is a hydrochloride salt with pka 9.5.
When the pH ranges from1.2 to 7.4, it shows a pH independent solubility profile. The
hydrophilic polymer Polyox® 303 is a nonionic polymer and its solubility is not sensitive
to pH. The result of pH effect on drug dissolution was shown in Figure 4-7. The drug
release profiles of H2 in three different media are very close to each other. Select water
release as reference, the f2 value of the simulated gastric fluid (SGF) is 67.68 and the
simulated intestinal fluid (SIF) is 76.99. The result suggests this novel matrix system
provides a pH independent dissolution profile for a pH insensitive drug. But for a pH
sensitive drug, the dissolution profile may change based on the solubility of drug in
different pH medium.
4.3.8 Drug release mechanism study
4.3.8.1 Optical microscopic observation
Figures 4-8 and 4-9 recorded the water penetration and components changes of
two colored tablet formulations of H0 and H2 during 12 hours dissolution. Formulation
H0 does not contain any hydrophilic polymer. The white drug powder was uniformly
distributed in the matrix before dissolution as described in Figure 4-8A and B. Upon
contacting with water, the surface drug dissolved in the water and left the pores on the
surface of the tablet (Figure 4-8B) and the pore size is as same as the size of undissolved
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Figure 4-8. Microscopic picture of colored tablets (H0) during dissolution
A: Tablet surface at 0 hour; B: Tablet cross section at 0 hour; C: tablet surface at 1 hour;
D: tablet cross section at 1 hour; E: Tablet surface at 6 hours; F: tablet cross section at 6
hours; G: tablet surface at 12 hours; F: tablet cross section at 12 hours.
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Figure 4-9. Microscopic picture of colored tablets (H2) during dissolution
A: Tablet surface at 0 hour; B: tablet cross section at 0 hour; C: tablet surface at 1 hour;
D: tablet cross section at 1 hour; E: tablet surface at 6 hours; F: tablet cross section at 6
hours; G: tablet surface at 12 hours; F: tablet cross section at 12 hours.
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drug. Figure 4-8D, E and F demonstrated the slow water penetration process through the
pores into the core of the tablet. As shown in Figure 4-8H, even water completely wet
the tablet at 12 hours, there are still around 40% drug remaining in the center of the tablet
and could not diffuse through the tightly matrix structure. As described in Table 4-7, the
geometric dimension of H0 kept constant during 12 hours dissolution. The slower water
penetration rate and the compacted tablet structure result incomplete release.
Formulation H2 contains 5% Polyox 303 and the color of Polyox 303 is orange in
the Figure 4-8. Initially, the hydrophilic polymer, drug and the co-processed excipient
were uniformly distributed in the matrix (Figure 4-9A and B). After 1h, the hydrophilic
polymer located on the surface was swollen and formed a viscous gel. The large pores
filled with viscous gel on the tablet surface were observed (Figure 4-9C). This gel can
prevent the rapid surface drug release initially. With the swelling of the hydrophilic
polymer, the tablet dimensions changed both radically and axially at 1 hour (Figure 4-9D
and Table 4-7). At 6 hours, the hydrophilic polymer located on the surface dissolved and
left the swollen pores on the surface for water penetration. The tablets continued to
expand and the water almost wetted the whole tablet at 6 hours. Due to the present of
large pores, water penetration rate for formulationH2 is much faster than formulation H0.
The geometric dimension of the tablet at 12 hours was similar to 6 hours as shown in
Table 4-7. This indicates the hydrophilic polymer was completely hydrated at 6 hours.
After 6 hours, the polymer erosion is the major activity of the hydrophilic polymer within
the tablet matrix. At 12 hours, highly porous structure of the tablet can be observed in
Figure 4-9G and 9H. Because the large pores generated while the dissolution, water can
easily penetrate through these large pores and extract drug from the matrix. Therefore
completely drug release can be expected from formulation H2.
4.3.8.2 Mathematic model fit
The dissolution profiles of three formulations containing different pore formers
were fitted to logarithm transformed power law equation and Peppas and Shalin equation.
The results were shown in Figures 4-10 and 4-11. All the three dissolution profiles
displayed a good fit to both the power law equation and Peppas and Shalin equation
(R2>0.98). The drug release mechanism can be determined by the n value which is the
slope of logarithm transformed power law equation and R/F ratio which can be calculated
from the Peppas and Shalin equation. The n value for P1 (lactose as pore former) is
slightly higher than 0.45, this suggest the major drug release is controlled by Fickian
diffusion. This is confirmed by the Peppas and Shalin equation. The k2 value for P1 in
Peppas and Shalin equation is negative. The negative value of k2 means the structure
relaxation can be neglected. The n value P2 formulation (Starch 1500 as pore former) in
power law equation is 0.5703. This value is higher than 0.45 and indicates both Fickian
diffusion and polymer relaxation play a role in controlling the drug release. The k2/k1
ratio is 0.206 and the R/F ratio for P2 formulation is always less than 1 within 12 hours
dissolution time. This indicates the Fickian diffusion is dominant mechanism for P2
tablets. For the H2 formulation (Polyox 303 as pore former), the n value is 0.6781. It is
also an anomalous transport mechanism. Both diffusion and polymer swelling take place.
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Table 4-7.

Tablets size change during dissolution

Time
0 hour
1 hour
6 hours
12 hours

H0
Thickness
Diameter
(mm)
(mm)
3.68
9.55
3.70
9.60
3.70
9.60
3.70
9.60
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H2
Thickness
Diameter
(mm)
(mm)
3.70
9.55
4.55
9.81
6.07
9.85
6.11
9.84

2
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P2: Y = 0.5703x + 1.431
R² = 0.9964
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lg Q%
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Figure 4-10. Power law equation fit
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The k2/k1 ratio for H2 is 0.892. When t <1.3 hours, R/F is less than 1. The Fickian
diffusion is the dominant release mechanism. This is diffusion is caused by the release of
the surface drug. When t>1.3 hours, the matrix relaxation is the dominant release
mechanism. This is caused by the polymer swelling and erosion.
4.4 Conclusions
A novel swellable porous matrix tablet was successfully developed by
incorporation of small amounts of hydrophilic polymer into the plastic inert matrix. The
drug release from this novel matrix formulation showed a limited burst release initially
with complete release at final stage.
The drug release rate from this matrix system is independent with the type and the
particle size of hydrophilic polymer and the pH of dissolution medium. The drug release
rate increased when the hydrophilic polymer concentration less than 5%. Further increase
the hydrophilic polymer concentration to 10% did not further increase the drug release
rate. The low viscosity grade hydrophilic polymer result rapid burst release and
incomplete final release, while middle to high viscosity grades of hydrophilic polymer
avoided these problems. The optical microscopy results revealed the initial gel formation
on the tablet surface with development of a swollen porous structure in the matrix
network during dissolution. The drug release is controlled by both drug diffusion and
polymer relaxation. The Fickian diffusion is the dominant release mechanism at initial
stage and the polymer relaxation becomes dominant thereafter.
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Chapter 5. Application of the Novel Matrix System on the Drugs with Different
Solubility
5.1 Introduction
The final objective of this work is to apply the plasticized cellulose acetate
excipient and the hydrophilic polymer involved novel matrix system to the sustained
release matrix tablets. In order to test the suitability of this swollen porous matrix system,
we selected three different drugs with different solubility as model drugs. A β-adrenergic
blocking agent propranolol hydrochloride with water solubility more than 150 mg/ml at
37°C was selected as the freely water soluble model drug [83]. Theophylline which used
for treatment of chronic asthma with water solubility of 9.9 mg/ml at 37°C was selected
as sparingly water soluble model drug [36]. The short acting sulphonyl urea drug
glipizide with solubility of 0.078 mg/ml in pH 6.8 and insoluble in water and acidic pH
was selected as poorly water soluble model drug [23, 84]. Propranolol hydrochloride and
glipizide all have a short elimination half-life and theophylline has a fairly narrow
therapeutic plasma concentration. The clinical effect of those drugs can be improved by
using sustained release formulations. The feasibility of the co-processed excipient and the
novel matrix system in these three drugs are evaluated by comparison of dissolution
profiles with USP specifications or commercial product.
5.2 Materials and Methods
5.2.1 Materials
Cellulose acetate with 39.8% acetyl content and 38 cp viscosity (CA 398-10 NF,
Eastman, Kingsport, TN) was used as the main polymer in this study. Triethyl citrate
(TEC), acetyltriethyl citrate (ATEC), acetyltributyl citrate (ATBC) and dibutyl sebacate
(DBS) (Morflex Inc., Greensboro, NC) were used as plasticizers. Milled dicalcium
phosphate dihydrate (milled DCP Innophos Inc., Cranbury, IL) were used as filler.
Magnesium stearate (Mallinckrodt, Paris, KY) was used as a lubricant. Propranolol
hydrochloride was used as water soluble model drug, Theophylline anhydrous (BASF,
Ludwigshafen, Germany) was used as sparing water soluble drug and glipizide was used
as poorly water soluble drug. Three different viscosity grades of HPC(Klucel®
EXF,GXF and HXF, Ashland, Wilmington, DE), high viscosity grade of polyethylene
oxide (Polyox® 303, Dow Chemical, Midland MI) and high viscosity grade of sodium
alginate (KELTONE® HVCR, FMC biopolymer, Philadelphia, PA) were selected as
hydrophilic polymers. Glucotrol XL® 10 mg (Pfizer, Peapack, NJ) was used as a
commercial product for dissolution profile comparison.
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5.2.2 Methods
5.2.2.1 Tablets preparation
5.2.2.1.1 Propranolol hydrochloride tablets
The tablet formulations were listed in Tables 5-1 and 5-2. The drug was mixed
with intragranular hydrophilic polymer by passing through 20 mesh sieve three times.
The mixture was compacted to form a ribbon on the TFC-LAB Micro Roller Compactor
(Vector, Marion, IA). The settings for the roller compactor are: Roller speed: 2rpm,
screw speed: 20rpm, roller pressure: 5 MPa. The ribbons were milled by the minioscillator mounted with an 18 mesh sieve. The dry granules were mixed with other
ingredients by passing through 16 mesh sieve for three times and then compressed on a
Carver Press (Carver Inc., Wabash, IN) by 3/8 inch flat face punch at 1.5 metric ton
compression force with 3 second dwell time. The target weight was 400mg.
5.2.2.1.2 Theophylline anhydrous tablets
The tablet formulations were listed in Table 5-3. The tablets were prepared by a
direct compression method. All the ingredients were mixed by passing through 20 mesh
sieve for 3 times. The mixture was compressed on a Carver Press (Carver Inc., Wabash,
IN) by 3/8 inch flat face punch at 1.5 metric ton compression force with 3 second dwell
time. The target weight was 400mg.
5.2.2.1.3 Glipizide tablets
The tablet formulations were listed in Tables 5-4 and 5-5. The tablets were
prepared by a direct compression method. All the ingredients were mixed by passing
through 20 mesh sieve for 3 times. The mixture was compressed on a Carver Press
(Carver Inc., Wabash, IN) by 1/4 inch flat face punch at 1.0 metric ton compression force
with 3 second dwell time. The target weight was 200 mg.
5.2.2.2 In vitro dissolution study
5.2.2.2.1 Propranolol hydrochloride and theophylline
The USP Apparatus II (Hanson SR-8 Plus, Hanson Research Corporation,
Chatsworth, CA) was used to evaluate the drug release. Three tablets from each batch
were tested. 900 ml of distilled water and pH 7.4 phosphate buffer at 37 ± 0.5°C was used
as the dissolution medium to evaluate the release of propranolol hydrochloride and
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Table 5-1.
Formulations for propranolol hydrochloride tablets prepared with
different intragranular hydrophilic polymers
Ingredients
Propranolol hydrochloride
Polyox® 303(intragranular)
HPC HXF (intragranular)
HPC GXF (intragranular)
Spray dried excipient F2
Magnesium Stearate
Total

PR1
20
5
0
0
74.5
0.5
100

Percentage (%)
PR2
20
0
5
0
74.5
0.5
100

PR3
20
0
0
5
74.5
0.5
100

Table 5-2.
Formulations for propranolol hydrochloride tablets prepared with
intragranular and extragranular hydrophilic polymers
Ingredients

Percentage (%)
PR4
PR5
20
20
5
0
0
5
5
5
69.5
69.5
0.5
0.5
100
100

Propranolol hydrochloride
HPC GXF(intragranular)
HPC EXF (intragranular)
Polyox® 303(extragranular)
Spray dried excipient F2
Magnesium Stearate
Total
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Table 5-3.
Formulations of theophylline tablets prepared with different
concentrations of hydrophilic polymers
Ingredients

T1
25
74.5
0
0.5
100

Propranolol hydrochloride
Spray dried excipient F2
Polyox® 303
Magnesium Stearate
Total

Percentage (%)
T2
25
69.5
5
0.5
100

T3
25
64.5
10
0.5
100

Table 5-4.
Formulations of glipizide tablets with different concentrations of coprocessed excipients
Ingredients
Glipizide
Spray dried excipient F2
Lactose 316
Magnesium Stearate
Total

Percentage (%)
G2
G3
5
5
7.5
10
87.0
84.5
0.5
0.5
100
100

G1
5
5
89.5
0.5
100

G4
5
20
74.5
0.5
100

Table 5-5.
Formulations of glipizide tablets prepared with different
concentrations of sodium alginate
Ingredients
Propranolol hydrochloride
Spray dried excipient F2
Lactose 316
Sodium Alginate HVCR
Magnesium Stearate
Total

G5
5
20
73.5%
1
0.5
100
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Percentage (%)
G6
5
20
72.5%
2
0.5
100

G7
5
20
71.5%
3
0.5
100

theophylline respectively. The paddle speed was 50rpm. The samples were taken at
predetermined time points for 12 hours. The absorbance of the solution was measured at
289 nm for propranolol hydrochloride and 274 nm for theophylline by a UVspectrophotometer (Perkin-Elmer Corporation, Norwalk, CT). The drug concentration
and the percentage of drug release were calculated by the software DissLab®.
5.2.2.2.2 Glipizide
The USP Apparatus II (Hanson SR-8 Plus, Hanson Research Corporation,
Chatsworth, CA) was used to evaluate the drug release. Three tablets from each batch
were tested. Hydrochloric acid (0.1 N, 750 ml) was used as the dissolution media for the
first 2 hours. Then, pH was adjusted to 6.8 by adding 250 ml of 1N tribasic phosphate.
The paddle speed is 50 rpm. The samples were taken at predetermined time points for 14
hours. The absorbance of the solution was measured at 287 nm by a UVspectrophotometer (Perkin-Elmer Corporation, Norwalk, CT). The drug concentration
and the percentage of drug release were calculated by the software DissLab®.
5.2.2.2.3 Similarity factor f2
The difference of drug dissolution profiles was evaluated by using f2 value as
described in Equation 5-1.
2 -0.5

f2 =50×log{[1+(1+1/n) ∑t=1 (Rt -Tt ) ]

×100}

(Eq. 5-1)

where f2 is a similarity factor, n is the number of sample times, Rt is the average
percentage of drug released at time t for the reference sample, Tt is the average
percentage of drug released at time t for the test sample. According to FDA’s guidance
for industry, if f2 values were greater than 50, the two dissolution profiles can be consider
as similar or equivalent.
5.2.2.3 Mathematic model fitting
5.2.2.3.1 Power law equation
Drug-release mechanism was first studied by fitting the dissolution data to the
power law equation [45].
Mt/ M∞=k*tn

(Eq. 5-2)

where Mt is cumulative amount of drug released at time t, M∞ is cumulative amount of
drug released at infinite time; k is release constant incorporating structural and geometric
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characteristics of the system, and n is the release exponent indicating the mechanism of
drug release.
The release exponent ‘n’ in the power law takes multiple values based on
geometry of the system. For a cylinder shape tablets, if n<0.45, the major release
mechanism is Fickian diffusion; if the n value >0.89, Case-II transport in which the
polymer relaxation is the rate limiting process; if n value between 0.45 and 0.89, the
“anomalous transport” takes place where both of drug diffusion and swelling of the
polymer are involved.
5.2.2.3.2 Peppas and Shalin equation
Peppas and Shalin equation is a modification of power law equation [50]. It was
performed by decoupling diffusion and “Case-II transport” with the following expression:
Mt/ M∞=k1*tm + k2*t2m

(Eq. 5-3)

where k1 and k2 are the release constants and m is the pure Fickian diffusion exponent.
The exponent m is related to the aspect ratio of the tablets. For the aspect ratio of tablet
around 3, the m value is 0.45. And m=0.45 was used in our study. First term in the right
hand of the Equation 5-3 represents the contribution of Fickian diffusion (F) and the
second term represents the contribution of tablet structure relaxation (R). R/F ratio can be
calculated using Equation 5-4:
R/F = k2*tm/k1

(Eq. 5-4)

The dominant drug release mechanism can be determined by the R/F ratio at any
given time during dissolution. The model fit was performed by the software GraphPad
Prism 4.
5.3 Results and Discussion
5.3.1 Propranolol hydrochloride matrix tablets
According to the dissolution results in Chapter 4, incorporation of the hydrophilic
polymer to the matrix significantly increase the drug release at final stage, but the initial
burst release still exists. In order to minimize the burst effect for a freely water soluble
drug, the roller compaction method was used in this chapter.
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5.3.1.1 The effect of roller compaction process on drug release
The Figure 5-1 displayed the effect of roller compaction of drug with hydrophilic
polymers on drug release. Since the dissolution profiles of the direct compression
formulations containing 5% Polyox® 303, HPC HXF and HPC GXF were very close
(data was not shown). We only selected the direct compression formulation H2 (5%
Polyox® 303) for comparison. The results shown in Figure 5-1 demonstrated the drug
release rate was affected by the roller compaction process as well as the polymer used in
this process. Roller compaction of the drug with the hydrophilic polymer can decrease the
drug release rate in this matrix system. This impact was more obvious at the final stage
than the initial stage. The hydrophobicity and the viscosity of the hydrophilic polymer
also play a role in drug release rate. The tablets prepared by more hydrophobic polymer
HPC and the middle viscosity grades of HPC showed a slower release rate than the more
hydrophilic polymer Polyox® 303 and the high viscosity grade HPC. Table 5-6 listed the
initial drug release (1 hour) and the final drug release (12 hours) for these four
formulations. The results showed not only a decrease in drug release in initial release for
all roller compacted formulations, but also a significant decrease at the final stage. The
decrease of the initial release might be due to the freely water soluble drug embedded in
the hydrophilic polymer. The viscous gel directly surrounding the drug particles can help
to reduce the rapid initial drug release. The hydrophilic polymer with more
hydrophobicity and less viscosity has less water absorption initially, therefore less drug
diffusion through the gel and an improved initial retarding effect was observed. The
decrease of the final drug release might due to reduction in the swellability of the
hydrophilic polymer during the roller compaction. Loss of the swellability of the
hydrophilic polymer will result in a less porous structure of the final tablets. Therefore
incomplete drug release is seen in the dissolution time studied.
5.3.1.2 The effect of the intragranular polymer on drug release
When a controlled release formulation is developed, typically less burst effect and
complete release are required. Roller compaction of the drug with the hydrophilic
polymer not only limited the burst release, but also suppressed the final release. In order
to reach complete release, five percent of Polyox® 303 was added extra granularly. The
purpose of the extragranular Polyox® 303 is to expand the tablet and generate the highly
porous tablet structure. Figure 5-2 displayed the effect of extragranular hydrophilic
polymer on the drug release. The percentages of initial and final drug release for these
four formulations were tabulated in Table 5-7. The extragranular Polyox® 303 only
increased the final drug release for roller compacted formulations and did not interfere
with the initial release. The formulation PR5 prepared with 5% intragranular low
viscosity grade HPC EXF and 5% extragranular Polyox® 303 showed slowest initial
release and complete final release. As shown in Table 5-8, the release profile of PR5
meets the USP requirements for propranolol hydrochloride sustained release formulation.
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Figure 5-1.

Effect of roller compaction on propranolol hydrochloride release
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Table 5-6.
The drug release results of formulations containing intragranular
hydrophilic polymers at 1 hour and 12 hours
Formulations
1 hour
H2 (5% Polyox® 303)
19.36±0.56
PR1 (5% intragranular Polyox® 303)
18.18±0.39
PR2 (5% intragranular HPC HXF)
16.10±0.61*
PR3 (5% intragranular HPC GXF)
14.40±0.45*
* Statistically significant difference with H2 formulation. (P< 0.05)
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12 hours
90.69±0.52
79.09±2.77*
76.81±1.81*
59.80±2.18*
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Figure 5-2. Effect of extragranular hydrophilic polymer on propranolol
hydrochloride release
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Table 5-7.
The drug release results of formulations containing intragranular and
extragranular hydrophilic polymers at 1 hour and 12 hours
Formulations
1 hour
H2 (5% Polyox 303)
19.36±0.56
PR3 (5% intragranular HPC GXF)
14.40±0.45*
PR4 (5% intragranular HPC GXF+5%
14.54±0.19*
extra granular Polyox® 303)
PR5 (5% intragranular HPC EXF+5%
11.20±0.51*
extra granular Polyox® 303)
* Statistically significant difference with H2 formulation. (P< 0.05)

12 hours
90.69±0.52
59.80±2.18*
82.88±1.78*
88.23±1.38

Table 5-8.
Comparison of propranolol hydrochloride tablets prepared from PR1
and USP specifications
Time
1h
3h
6h
12h

Requirements
<20%
20-45%
45%-60%
>80%

115

PR5
11.20 ±0.51
31.97±0.66
49.90±0.39
88.23±1.38

5.3.1.3 Mathematic model fit
The dissolution profiles of formulation H2 (5% Polyox 303), PR1 (5%
intragranular Polyox® 303) and PR5 (5% intragranular HPC EXF+5% extra granular
Polyox 303) were fitted to logarithm transformed power law equation. The results were
displayed in Figure 5-3. Three dissolution profiles all exhibit good fit for power law
equation (R2>0.99). The n values for formulation H2 and PR1 falls in the range of 0.450.89 which indicates both Fickian diffusion and matrix relaxation are responsible for
controlling the drug release. Loss of swellability of hydrophilic polymer in roller
compaction results less polymer relaxation, therefore smallest n value for formulation
PR1 was observed. The n value for formulation PR5 is above 0.89 which indicates the
dominant drug release mechanism is matrix relaxation. This result was confirmed by
Peppas and Shalin equation (Figure 5-4). The k1 value for formulation PR5 is negative
which means the Fickian diffusion can be neglected. This results suggests roller
compaction of the freely water soluble drug with the low viscosity hydrophilic polymer
can suppress the initial rapid drug diffusion and change the drug release mechanism from
Fickian diffusion to matrix relaxation.
5.3.2 Theophylline anhydrous tablets
5.3.2.1 Formulation development
Theophylline is a week acid with pka 8.8 [85]. The solubility of theophylline
remains constant when the pH ranges from1 to 6.8. The solubility increases as the
environmental pH climbing to 7.0 and above. This is BCS I drug with high solubility and
high permeability. According to USP test method, pH 7.4 phosphate buffer is used as the
dissolution medium for theophylline sustained release tablets. The formulation
development of theophylline sustained release tablets in our study was carried by
incorporating different concentration of hydrophilic polymer to the plastic inert matrix
system. Three formulations were tried and the dissolution profiles were displayed in
Figure 5-5. The formulation T1 prepared with only plasticized co-processed excipient
showed a significant burst release and the incomplete final release. When we
incorporated hydrophilic polymer Polyox 303 to the above system, unlike rapid gel
diffusion rate of freely water soluble drug propranolol hydrochloride initially, the
sparingly water soluble drug theophylline has a limited diffusion through the viscous gel.
Therefore the initial release was suppressed by incorporating the hydrophilic polymer.
When the concentration of the hydrophilic polymer increased from 5 to 10%, the initial
release was further decreased. The significant increase of the final release (p<0.05) were
observed for both 5% and 10% Polyox 303 formulations. The solubility of theophylline is
only one tenth of propranolol hydrochloride and could not generate enough osmotic
pressure inside the tablet. A larger amount of hydrophilic polymer was required in order
to have a complete final release. The dissolution profile of formulation T3 showed a good
satisfaction with the USP requirements as shown in Table 5-9.
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Power law equation fit of propranolol hydrochloride release profile
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Effect of hydrophilic polymer concentrations on theophylline release
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Table 5-9.
Comparison of theophylline tablets prepared from T3 and USP
specifications
Time
1h
2h
4h
5h
8h

USP requirements

T3

3-15%
12-30%
25-50%
30-60%
55-75%

8.64±0.94
16.63±1.22
31.06±1.49
38.59±1.59
58.59±1.77
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5.3.2.2 Mathematic model fit
The dissolution profiles of three theophylline formulations were fitted to
logarithm transformed power law equation as shown in Figure 5-6. Formulation T1
(without hydrophilic polymer) showed a typical diffusion controlled drug release with n
value less than 0.45. Formulation T2 (5% Polyox 303) and T3 (10 Polyox 303) all
showed the diffusion and structure relaxation combined release mechanism with n value
between 0.45-0.89. The dominant drug release mechanism of T2 and T3 can be
determined by the results of Peppas and Shalin equation fit (Figure 5-7). The k2/k1 ratio
for T2 is 1.1 which indicates the diffusion is the major mechanism initially and the
polymer relaxation is dominant afterwards. The k1 value for T3 formulation is negative
which indicate the diffusion mechanism is minimal in controlling the drug release. The
drug release difference between T2 and T3 can be explained by the difference of gel
strength initially. The higher gel strength was obtained by the formulation T3 which
containing more hydrophilic polymer. The higher gel strength effectively prevent the
initial burst release for a sparingly water soluble drug theophylline.
5.3.3 Glipizide tablets
Glipizide is a weak acid with pka 5.9. It is insoluble in the pure water and shows a
pH dependent solubility. The solubility of glipizide is 0.078mg/ml in pH 6.8 buffer and
practical insoluble in acidic pH. As suggest in USP, the dissolution test of glipizide
sustained release formulations was performed in 0.1 N hydrochloric acid solution for 2
hours, then pH 6.8 buffer for another 12 hours in our study. The commercialized glipizide
sustained release formulation is an osmotic pump tablet named Gluctrol XL®. It is
bilayer tablet and coated by a semi-permeable membrane with a laser drilled hole on the
surface [23]. The drug release can be precisely controlled from this device, but the
manufactures of osmotic pump devices is complicated and expensive involving many
process variables. In this chapter, we are trying to develop a direct compressed matrix
tablet to control the release of glipizide by using the plasticized co-processed excipient.
5.3.3.1 The effect of co-processed excipient on drug release
For development of sustained release inert matrix tablet for a water insoluble
drug, a pore former is essential to achieve the complete release. The traditional pore
former lactose monohydrate was tried first. In order to obtain complete release for
glipizide, a large amount of lactose in the formulation was required and the amount of coprocessed excipient is relatively small. For the purpose of convenience, we used the
concentration of co-processed excipient to represent each of the formulation. The
dissolution profiles of the reference tablet Gluctrol XL® and tablets prepared with
different concentrations of co-processed excipients were displayed in Figure 5-8.
Because glipizide is insoluble in acidic pH, all the tablets in Figure 5-8 showed a delayed
release profile of two hours. Gluctrol XL® exhibits nearly zero order release between 214 hours. Except the formulation G4 which contains 20% co-processed excipient, all
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other formulations prepared with the co-processed excipient and lactose in Figure 5-8
were disintegrated during dissolution. Because the hydrophobic nature of the glipizide
and certain shape and network structure of each disintegrated subunit were maintained
during the dissolution, the sustained drug release profile still can be achieved for these
formulations. Disintegration of the tablet significantly increases the surface area exposed
in dissolution medium and reduces the diffusion pathway of the drug, therefore helping to
reach complete final release. But the particle size of each disintegrated subunit is not
identical for different tablets prepared with same formulation which causes a large
variation in the dissolution within the batches as shown in Figure 5-8. Considering the f2
values for each formulation, only formulation G3 prepared with 7.5% co-processed
excipient is greater than 50. (f2=52.08) This indicates the dissolution profile of G3 is
similar to the reference product Gluctrol XL® and can be further evaluated by an in vivo
bioequivalence study.
5.3.3.2 The effect of hydrophilic polymer on drug release
The formulation development of glipizide sustained release matrix tablet was also
performed by incorporating different concentrations of the hydrophilic polymer in the
matrix system. Since the glipizide is a poorly soluble drug and requires more channels for
diffusion, the proper amount of lactose combined with 20% co-processed excipient were
used to construct the matrix system. In order to mimic the 2 hours delayed release as the
reference tablet, a pH sensitive polymer sodium alginate was selected. Sodium alginate
is insoluble and cannot swell in acidic pH but it will hydrate and swell in neutral and
basic pH. Incorporating sodium alginate in the matrix tablet can help to keep tablet
structure in acid pH and generate enough porous for drug diffusion in neutral and basic
pH. The effect of the concentrations of hydrophilic polymer on drug release was shown
in Figure 5-9. All the tablets in Figure 5-9 remained intact during 14 hours dissolution.
The drug release rate increasing as the concentration of sodium alginate increased. Since
the tablets did not disintegrate during dissolution, less batch variation (SD<4%) of
dissolution was observed. The f2 value for formulation G6 containing 2% sodium
alginate and 20% co-processed excipient is greater than 50 (f2=65.03). This suggests
formulation G6 has the similar dissolution profile with reference tablet Gluctrol XL®.
5.3.3.3 Mathematic model fit
The logarithm transformed power law equation was used to fit the dissolution
profiles of formulation G2 and G5 (Figure 5-10). Since all the formulations exhibit two
hours delay, the mathematic model fit all took 2 hours as starting point. The formulation
G2 (7.5% co-processed excipient) showed a combined diffusion and structural relaxation
controlled drug release mechanism with n value between 0.45 and 0.89. The dominant
drug release mechanism of G2 can be derived from Peppas and Shalin equation fit
(Figure 5-11). The k2/k1 ratio for G2 is 1.03 and the R/F ratio can be calculated from
Equation 5-4. The result indicates the diffusion is the dominant mechanism within the
first hour and the structure relaxation is dominant afterwards. Because the disintegrating
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Figure 5-11. Peppas and Shalin equation fit of glipizide release profiles

128

12

of G2 tablets took place in the first hour, the surface drug diffusion is the major release
mechanism. After the tablet completely disintegrated, the disintegrated particles were in
charge of controlling the drug release and the release mechanism was switched to
structure relaxation after 1 hour. Formulation G6 (20% co-processed excipient +2.0%
sodium alginate) showed structural relaxation controller drug release with n value greater
than 0.89. The k1 value of formulation G6 in Peppas and Shalin equation is negative
which confirmed the dominant drug release mechanism is structural relaxation.
5.4 Conclusions
The sustained release matrix tablets for three different drugs with different
solubility were successfully developed by using the novel swollen porous matrix system.
The optimized formulations for these three drugs either meet the USP specifications or
have similar dissolution profile as the commercial product. For a freely water soluble
drug propranolol hydrochloride, a novel roller compaction method was successfully
applied to reduce the initial burst release. The tablets prepared by the roller compacted
granules showed suppressed burst release and complete final release. The power law
equation and Peppas and Shalin revealed the drug release was controlled by the structure
relaxation. For sparingly water soluble drug theophylline, incorporating the hydrophilic
polymer can successfully reduce the burst release as well as improve the final release.
When 10% percent of hydrophilic polymer presents in the formulation, the initial burst
was further reduced and the drug release mechanism is switched from initial diffusion
controlled to completely structure relaxation controlled. Two successful sustained
release formulations of poorly water soluble drug glipizide were obtained by using the
plasticized co-processed excipient. Both of them have similar dissolution profile as the
commercial product Gluctrol XL®. But the formulation prepared with lactose as pore
former showed a big variation in dissolution profile while another formulation prepared
with both lactose and hydrophilic polymer as pore former exhibited less variation in
dissolution profile and higher f2 value.
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